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1.INTRODUCTION
1.1. Mouth Dissolving Tablets (Kuchekar B.S et al., 2003)
Drug delivery via the oral mucosa is a promising route, when one wishes to
achieve a rapid onset of action or improved bioavailability for drugs with high first-
pass metabolism. Thus, there is a growing interest in developing alternative dosage
forms, i.e. orally fast disintegrating tablets, which allow a rapidly dissolving drug to
absorb directly into the systemic circulation through the oral mucosa. These kinds of
dosage forms are also convenient for children, elderly patients with swallowing
difficulties, and in the absence of potable liquids. However, in addition to formulation
considerations, the properties of the active compound have to be appropriate in order
to achieve drug delivery into systemic circulation after intra oral administration. The
drug has to be soluble, fast dissolving and stable, and this might represent an obstacle
for lipophilic drugs. Due to the small volume of saliva in the oral cavity, the
therapeutic dose of an intra oral drug must be relatively small.
Among the different routes of administration, the oral route of administration
continues to be the most preferred route due to various advantages including ease of
ingestion, avoidance of pain, versatility and most importantly patient compliance. The
different dosage forms include tablets and capsules. The important drawback of these
dosage forms for pediatric and geriatric patients is being difficulty in swallowing.
Nearly35% of the general population, especially the elderly patients and children
suffer from dysphagia or difficulty in swallowing, which results in high incidence of
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noncompliance   and ineffective therapy. Swallowing problems also are very common
inyoung individuals because of their poorly developed muscular and nervous systems.
Other groups who may experience problems in swallowing conventional oral dosage
forms are the patients with tremors of extremities, mentally ill, developmentally
disabled, non co-operative patients and patients with reduced liquid intake plans or
patients suffering from nausea. The swallowing problems are also common in some
cases such as patients with motionsickness, sudden episodes of allergic attack or
coughing and due to lack of water.
To overcome these problems, formulators have considerably dedicated their
effort to develop a novel type of tablet dosage form for oral administration, i.e., one,
which disintegrates and dissolves rapidly in saliva without the need for drinking water.
The tablet is placed in the mouth, allowed to disperse or dissolve in the saliva. These
tablets usually dissolve within 15 seconds to 2 minutes. The faster the drug goes into
solution, the quicker the absorption and onset of clinical effect.
Less frequently, they are designed to be absorbed through the buccal and
oesophageal mucosa as the saliva passes into the stomach. In the latter case, the
bioavailability of a drug from rapidly disintegrating tablets may be even greater than
that observed for other standard dosage forms.
The fast dissolving tablets also offer advantages over other oral dosage forms
such as effervescent tablets, suspensions, chewing gum or chewing tablets, which are
commonly used to enhance patient compliance.
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The advantages of rapidly disintegrating tablets are being recognized in both
industry and academia. Their growing importance was underlined recently when the
European Pharmacopoeia adopted the term mouth dissolving tablet as a “tablet to be
placed in the mouth where it disperses rapidly before swallowing.
1.1.1. Anatomic and Physiologic Features of the Oral Cavity (Anne Waugh , 2006)
The surface area of the oral mucosa is about 100 cm2. Three different types of
oral mucosa are recognized: the mucosa, the lining mucosa, and the specialized
mucosa. The masticatory mucosa, representing 25% of the total oral mucosa, is100–
200μm thick and covers the gingiva and the hard palate. It is tightly attached to
underlying structures and subjected to abrasion and shear stress during mastication.
The lining mucosa (60% of the total oral mucosa) is 500–800μm thick and covers the
lips, cheeks, soft palate, lower surface of the tongue and the floor of the oral cavity.
The specialized mucosa (15% of the total oral mucosa) is present on the dorsum of the
tongue and is involved in taste.
1.1.1.1. Buccal Epithelium:
The buccal epithelium is a non-keratinized stratified squamous epithelium,
composed of multiple layers of cells that show different patterns of maturation
between the deepest cells and the surface. The basal cells of the buccal epithelium are
capable of division and maintain a constant epithelial population as cells move toward
the surface. Tissue homeostasis requires differentiation followed by migration and
desquamation of the superficial cells. The prickle cells (intermediate layer) accumulate
lipids and cytokeratins of low molecular weight that do not aggregate to form
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filaments. An intracellular lipid portion is packaged in small organelles called
membrane-coating granules or lamellar granules. Such granules migrate towards the
apical surface of the cell, where their membrane fuses with the cell membrane and
their lipid content is extruded in the extracellular space. The buccal epithelium lacks
tight junctions, which are common to intestinal and nasal mucosa, but is endowed with
gap junctions, glydesmosomes and hemidesmosomes, which are loose intercellular
links. The epithelium rests on the basal membrane, an irregular saliva continuous
interface between the epithelium and the connective tissue. The basal membrane
anchors the epithelium to the connective tissue and improves the barrier function of
the epithelium, preventing large molecules from passing through the oral mucosa.
Although buccal absorption is not the specific goal of oral fast- dissolving
tablets, this can occur when the drug is released in the oral cavity in contact with
buccal mucosa. The drug transport mechanism through the buccal mucosa involves
two major routes:
 Transcellular (intracellular)
 Paracellular (intercellular)
The transcellular route involves passage through the cellular membranes with a
polar and a lipid domain, while the paracellular route essentially consists of passive
diffusion through the extracellular lipid domain. It is generally recognized that the
lipid matrix of the extracellular space plays an important role in the barrier function of
the paracellular pathway, especially with compounds that are hydrophilic and have a
high molecular weight, such as peptides.
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1.1.1.2. Vascularization of the Oral Mucosa
Arterial, venous and lymphatic capillaries penetrate the multi- layered
epithelium, infiltrating the connective tissue. The oral mucosa is primarily supplied by
the external carotid artery, which serves the large buccal blood vessels. The floor of
the mouth, the root of the tongue and the cheek mucosa are the most highly
vascularized areas. Vascular drainage from the oral mucosa is primarily via the
lingual, facial and retromandibular veins, which flow together into the internal jugular
vein. This is the mechanism responsible for by passing first-pass hepatic metabolism.
1.1.1.3. Salivary Flow
Saliva is the medium for disintegrate or dissolution for drug formulations
designed to disintegrate/dissolve in the oral cavity; for this reason, the properties of
saliva are crucial to oral fast-dissolving tablets. The saliva is primarily secreted in the
oral cavity by parotid, submandibular (submaxillary) and sublingual glands, and also
by numerous minor glands. The main constituent of saliva is water (99.5% w/v). The
remaining 0.5% w/v consists of dissolved compounds; in fact, saliva is a hypotonic
solution (150–200 mOsm) compared with extracellular fluids (300 mOsm). The
principal components of saliva are: inorganic electrolytes (0.2% w/v), including
sodium, potassium, calcium, magnesium, bicarbonate and phosphates; gases (carbon
dioxide, nitrogen, oxygen); nitrogen products such as urea and ammonia; ascorbic acid
(vitamin C); creatinine; and mucins (high-molecular-weight glydesmosomes
coproteins, which render the saliva viscous and adhesive). Saliva also contains amino
acids and proteins, digestive enzymes (salivary α-amylase [ptyalin], lipase, maltase,
LORATADINE MDT – AS NOVEL APPROACH INTRODUCTION
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 6
and lysozyme with antibacterial activity), proteolytic enzymes (moderate levels of
esterase, carbohydrases and phosphatases), serum albumin and immunoglobulins.
Saliva has a weak buffering capacity and its normal pH value is slightly
acid (pH 6-7); however, salivary flow pH can range from 5.3 (low flow) to 7.8 (peak
flow). The accepted range of normal salivary flow is approximately 0.1–0.2 ml/min,
increasing to 7 ml/min upon stimulation. Saliva wets the entire oral cavity and the
resulting mucus layer ranges from 1 to 400μm in thickness, forming a physical barrier
to drug permeation and a useful substrate for mucoadhesive drug delivery systems.
1.1.2. The Ideal Characteristics of Mouth Dissolving Tablet (Kuchekar B.S, 2003)
Requires no water for oral administration, yet dissolve or disintegrate in the
mouth in a matter of seconds
Allow high drug loading.
Bitter taste to be masked.
Have a pleasant mouth feel.
Leave minimal or no residue in the mouth after oral administration.
Be portable without fragility concerns.
Exhibit low sensitivity to environmental conditions such as humidity and
temperature.
Allows the manufacture of tablets using conventional processing and
packaging equipment at low costs
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1.1.3. Requriment of Mouth Dissolving Tablets an ideal MDT should
(Abhishek Gupta et al.,2010)
Require no water for oral administration, yet dissolve /disperse/ disintegrate in
mouth in a matter of seconds.
Have small to moderate molecular weight.
Good stability in water and saliva, to permeate oral mucosal tissue.
Ability to diffuse and partition into the epithelium of the upper GIT (log P>1,
or preferably>2).
Have an acceptable taste masking property.
Be harder and less friable.
Be compatible with taste masking.
Have a pleasing mouth feel.
Leave minimal or no residue in the mouth after oral administration.
Exhibit low sensitivity to environmental conditions as humidity and
temperature.
Allow the manufacture of tablet using conventional processing and packaging
equipment at low cost
1.1.4. Advantages of MDDDS (Abhishek Gupta et al.,2010)
1. Ease of administration to patients who cannot swallow, such as the
elderly,   strokvictims and bedridden patients; patients who should not
swallow, such as renalfailure patients; and who refuse to swallow, such as
paediatrics, geriatric and psychiatric patients.
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2. Patient’s compliance for disabled bedridden patients and for travelling and
busy people, who do not have ready access to water.
3. Good mouth feel property of MDDDS helps to change the basic view of
medication as "bitter pill", particularly for paediatric patients due to improved
taste of bitter drugs.
4. Convenience of administration and accurate dosing as compared to liquid
Formulations.
5. Benefit of liquid medication in the form of solid preparation.
6. More rapid drug absorption from the pre-gastric area i.e. mouth, pharynx and
oesophagus which may produce rapid onset of action.
7. Pregastric absorption can result in improved bioavailability, reduced dose and
improved    clinical performance by reducing side effects.
Figure 1.1: Diagram Showing Advantages of MDT
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1.1.5. Disadvantages/Limitations of Mdts:
(Kuchekar B.S, 2003, Rangasamy Manivannan, 2009)
Certain drugs cannot be formulated as MDT’s because of the following limitations:
 The major disadvantage of MDTs is its mechanical strength.
 Several MDTs are hygroscopic and cannot maintain physical integrity under
normal condition from humidity which calls for specialized product packaging.
 MDTs are very porous and soft-moulded matrices or compressed into tablets
with very low compression force, which makes the tablets friable and/or brittle
which are difficult to handle, often requiring specialized peel-off blister
packaging.
 Bitter drugs or drugs with a disagreeable odour are difficult to formulate as
MDTs. Special precautionary measures have to be taken before formulating
such type of drugs.
1.1.6.   Challenges To Develop Mdts: (Suresh Bandari et al., 2010)
 Achieve rapid disintegrate of tablet.
 Avoid increase in tablet size.
 Possess sufficient mechanical strength.
 Leave minimum or no residue in mouth.
 Protection from moisture.
 Good package design.
 Compatible with taste masking technology.
 Not affected by drug properties
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1.1.7. Need of Fast Disintegrating Tablets:
The need for non-invasive delivery systems continues due to patients' poor
acceptance and compliance with existing delivery regimes, limited market size for
drug companies and drug uses, coupled with high cost of disease management.
The current needs of the industry are improved solubility/stability, biological
half-life and bioavailability enhancement of poorly absorbed drugs. Key issues facing
the biopharma industry are to improve safety (decreasing gastrointestinal side effects),
improve efficacy for organ targeting, and improved compliance via sustained release
or easy to swallow.
Developing new drug delivery technologies and utilizing them in product
development is critical for pharmaceutical companies to survive.
Pharmaceutical marketing is another reason for the increase in available fast-
dissolving/disintegrating products. As a drug entity nears the end of its patent life, it is
common for pharmaceutical manufacturers to develop a given drug entity in a new and
improved dosage form. A new dosage form allows a manufacturer to extend market
exclusivity, while offering its patient population a more convenient dosage form or
dosing regimen. In this regard, fast-dissolving/disintegrating tablet formulations are
similar to many sustained release formulations that are now commonly available. An
extension of market exclusivity, which can be provided by a fast-
dissolving/disintegrating dosage form, leads to increased revenue, while also targeting
underserved and under-treated patient populations. Although the cost to manufacture
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these specialized dosage forms exceeds that of traditional tablets, this additional cost is
not being passed on to the consumer.
Generally, the following points are considered for patient compliance in case
of Epileptic patients,
 A rapid onset of action is necessary for immediate relief.
 Patient has difficulty to swallow tablet or any another dosage form when
unconscious.
 Geriatrics has difficulty to swallow the dosage form.
Considering the above points, Patient convenience and compliance
oriented research has resulted in bringing out safer and newer drug delivery
systems. Recently Fast dissolving drug delivery systems have started gaining
popularity and acceptance with increased consumer choice, for the reason of
rapid disintegrate or dissolution, self administration even without water.
1.1.8. Salient Features of Mouth Dissolving Drug Delivery System (MDDDS)
 Ease of administration to pediatric, geriatric and psychiatric patients who
refuse to swallow a tablet.
 Convenient for administration and accurate dosing as compared to liquids.
 No need of water to swallow the dosage form, which is highly convenient
feature for patients who are depressed.
 Good mouth feel property of MDDDS helps to change the basic impression of
medication as ‘Bitter Pill’ particularly for pediatric patients.
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 As ODTs are unit solid dosage forms, they provide good stability, accurate
dosing, easy manufacturing, small packaging size, and easy to handle by
patients.
 Rapid dissolution and absorption of drug, which may produce rapid onset of
action.
 Some drugs are absorbed from the mouth, pharynx and oesophagus as the
saliva passes down into the stomach, which enhances bioavailability of drugs
by avoiding hepatic metabolism.
 Ability to provide advantage of liquid medication in the form of solid
preparation.
1.2. Methodology Employed For Mouth Dissolving Formulations
(Abhishek Gupta et al.,2010)
1.2.1. Melt granulation
Melt granulation technique is a process by which pharmaceutical powders are
efficiently agglomerated by a meltable binder. The advantage of this technique
compared to a conventional granulation is that no water or organic solvents is needed.
Because there is no drying step, the process is less time consuming and uses less
energy than wet granulation. It is a useful technique to enhance the dissolution rate of
poorly water-soluble drugs, such as griseofulvin. This approach to prepare FDT with
sufficient mechanical integrity, involves the use of a hydrophilic waxy binder
(Superpolystate, PEG – 6 – stearate). Superpolystate is a waxy material with a
melting point of 33–37°C and a HLB value of 9. So it will not only act as a binder and
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increase the physical resistance of tablets but will also help the disintegrate of the
tablets as it melts in the mouth and solublises rapidly leaving no residues.
1.2.2. Phase transition process
It is concluded that a combination of low and high melting point sugar
alcohols, as well as a phase transition in the manufacturing process, are important for
making FDTs without any special apparatus. FDT were produced by compressing
powder containing erythritol (melting point: 122 °C) and xylitol (melting point:
93- 95 °C), and then heating at about 93 °C for 15 min. After heating, the median pore
size of the tablets was increased and tablet hardness was also increased. The increase
of tablet hardness with heating and storage did not depend on the crystal state of the
lower melting point sugar alcohol.
1.2.3.   Sublimation
In this method a subliming material like camphor, is removed by sublimation
from compressed tablets and high porosity is achieved due to the formation of many
pores where camphor particles previously existed in the compressed tablets prior to
sublimation of the camphor. A high porosity was achieved due to the formation of
many pores where camphor particles previously existed in the compressed mannitol
tablets prior to sublimation of the camphor. These compressed tablets which have high
porosity (approximately 30%) rapidly dissolved within 15 seconds in saliva. Granules
containing nimusulide, camphor, crospovidone, and lactose were prepared by wet
granulation technique. Camphor was sublimed from the dried granules by vacuum
exposure. Conventional methods like dry granulation, wet granulation and direct
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compression with highly soluble excipients, super disintegrants and/or effervescent
systems can also be used.
1.2.4. Three-dimensional Printing (3DP)
Three-dimensional printing (3DP) is a rapid prototyping (RP) technology.
Prototyping involves constructing specific layers that uses powder processing and
liquid binding materials. A novel fast dissolving drug delivery device (DDD) with
loose powders in it was fabricated using the three dimensional printing (3DP) process.
Based on computer-aided design models, the DDD containing the drug acetaminophen
were prepared automatically by 3DP system. It was found that rapidly disintegrating
oral tablets with proper hardness can be prepared using TAG. The rapid disintegrate of
the TAG tablets seemed due to the rapid water penetration into the tablet resulting
from the large pore size and large overall pore volume.
1.2.5.   Mass Extrusion
This technology involves softening of the active blend using the solvent
mixture of water soluble polyethylene glycol and methanol and expulsion of softened
mass through the extruder or syringe to get a cylindrical shaped extrude which are
finally cut into even segments using heated blade to form tablets. This process can also
be used to coat granules of bitter drugs to mask their taste.
1.2.6. Spray drying
In this technique, gelatin can be used asa supporting agent and as a matrix,
mannitol as a bulking agent and sodium starch glycolate or croscarmellose or
crospovidone are used as superdisintegrants. Tablets manufactured from the spray-
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dried powder have been reported to disintegrate in less than 20 seconds in aqueous
medium. The formulation contained bulking agent like mannitol and lactose, a
superdisintegrant like sodium starch glycolate & croscarmellose sodium and acidic
ingredient (citric acid) and/or alkaline ingredients (e.g. sodium bicarbonate). This
spray-dried powder, which compressed into tablets showed rapid disintegrate and
enhanced dissolution. Maximum drug release and minimum disintegrate time were
observed with Kollidon CL excipient base as compared to tablets prepared by direct
compression, showing the superiority of the spray dried excipient base technique over
direct compression technique.
1.2.7. Cotton Candy Process
The FLASHDOSE® is a MDDDS manufactured using Shearform™
technology in association with Ceform TI™ technology to eliminate the bitter taste of
the medicament. The Shearform technology is employed in the preparation of a matrix
known as ‘floss’, made from a combination of excipients, either alone or with drugs.
The floss is a fibrous material similar to cotton-candy fibers, commonly made of
saccharides such as sucrose, dextrose, lactose and fructose at temperatures ranging
between 180–266 °F. However, other polysaccharides such as polymaltodextrins and
polydextrose can be transformed into fibers at 30–40% lower temperature than
sucrose. This modification permits the safe incorporation of thermolabile drugs into
the formulation. The tablets manufactured by this process are highly porous in nature
and offer very pleasant mouthfeel due to fast solubilization of sugars in presence of
saliva. The manufacturing process can be divided into four steps as detailed below.
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1.2.7.1. Floss Blend
In this step, 80% sucrose in combination with mannitol/dextrose and 1%
surfactant is blended to form the floss mix. The surfactant acts as a crystallization
enhancer in maintaining the structural integrity of the floss fibers. It also helps in the
conversion of amorphous sugar into crystalline form from an outer portion of
amorphous sugar mass and subsequently converting the remaining portion of the mass
to complete crystalline structure. This process helps to retain the dispersed drug in the
matrix, thereby minimizing migration out of the mixture.
1.2.7.2. Floss Processing
The floss formation machine uses flash heat and flash flow processes to
produce matrix from the carrier material. The machine is similar to that used in
‘cotton-candy’ formation which consists of a spinning head and heating elements. In
the flash heat process, the heat induces an internal flow condition of the carrier
material. This is followed by its exit through the spinning head (2000–3600 rpm) that
flings the floss under centrifugal force and draws into long and thin floss fibers, which
are usually amorphous in nature.
1.2.7.3. Floss Chopping and Conditioning
This step involves the conversion of fibers into smaller particles in a high shear
mixer granulator. The conditioning is performed by partial crystallization through an
ethanol treatment (1%) which is sprayed onto the floss and subsequently evaporated to
impart improved flow and cohesive properties to the floss.
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1.2.7.4. Blending and Compression
Finally, the chopped and conditioned floss fibers are blended with the drug
alongwith other required excipients and compressed into tablets. In order to improve
the mechanical strength of the tablets, a curing step is also carried out which involves
the exposure of the dosage forms to elevated temperature and humidity conditions, (40
°C and 85% RH for 15 min). This is expected to cause crystallization of the floss
material that results in binding and bridging to improve the structural strength of the
dosage form.
1.2.8.    Tablet Molding
Molding process is of two type’s i.e. solvent method and heat method. Solvent
method involves moistening the powder blend with a hydro alcoholic solvent followed
by compression at low pressures in molded plates to form a wetted mass (compression
molding). The solvent is then removed by air-drying. The tablets manufactured in this
manner are less compact than compressed tablets and posses a porous structure that
hastens dissolution. The heat molding process involves preparation of a suspension
that contains a drug, agar and sugar (e.g. mannitol or lactose) and pouring the
suspension in the blister packaging wells, solidifying the agar at the room temperature
to form a jelly and drying at 30ºC under vacuum. The mechanical strength of molded
tablets is a matter of great concern. Binding agents, which increase the mechanical
strength of the tablets, need to be incorporated. Taste masking is an added problem to
this technology. The taste masked drug particles were prepared by spray congealing a
molten mixture of hydrogenated cottonseed oil, sodium carbonate, lecithin,
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polyethylene glycol and an active ingredient into a lactose based tablet triturate form.
Compared to the lyophillization technique, tablets produced by the molding technique
are easier to scale up for industrial manufacture.
1.2.9.    Lyophilization or Freeze-Drying
Freeze drying is the process in which water is sublimed from the product after
it is frozen. This technique creates an amorphous porous structure that can dissolve
rapidly. A typical procedure involved in the manufacturing of ODT using this
technique is mentioned here. The active drug is dissolved or dispersed in an aqueous
solution of a carrier/polymer. The mixture is done by weight and poured in the walls
of the preformed blister packs. The trays holding the blister packs are passed through
liquid nitrogen freezing tunnel to freeze the drug solution or dispersion. Then the
frozen blister packs are placed in refrigerated cabinets to continue the freeze-drying.
After freeze-drying the aluminum foil backing is applied on a blister-sealing machine.
Finally the blisters are packaged and shipped. The freeze-drying technique has
demonstrated improved absorption and increase in bioavailability. The major
disadvantages of lyophillization technique are that it is expensive and time consuming;
fragility makes conventional packaging unsuitable for these products and poor
stability under stressed conditions.
1.2.10.   Direct Compression
Direct compression represents the simplest and most cost effective tablet
manufacturing technique. This technique can now be applied to preparation of ODT
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because of the availability of improved excipients especially superdisintegrants and
sugar based excipients.
1.2.10.1. Superdisintegrants
In many orally disintegrating tablet technologies based on direct compression,
the addition of superdisintegrants principally affects the rate of disintegrate and hence
the dissolution. The presence of other formulation ingredients such as water-soluble
excipients and effervescent agents further hastens the process of disintegrate. For the
success of fast dissolving tablet, the tablet having quick dissolving property which is
achieved by using the super disintegrants, Some important examples of super
disintegrants are given in Table 1 with their mechanism of action.
1.2.10.2. Sugar Based Excipients
This is another approach to manufacture ODT by direct compression. The use
of sugar based excipients especially bulking agents like dextrose, fructose, isomalt,
lactilol, maltilol, maltose, mannitol, sorbitol, starch hydrolysate, polydextrose and
xylitol, which display high aqueous solubility and sweetness, and hence impart taste
masking property and a pleasing mouthfeel. Mizumito et al have classified sugar-
based excipients into two types on the basis of molding and dissolution rate.
1.2.11. Nanonization
A recently developed Nanomelt technology involves reduction in the particle
size of drug to nanosize by milling the drug using a proprietary wet-milling technique.
The nanocrystals of the drug are stabilized against agglomeration by surface
adsorption on selected stabilizers, which are then incorporated into MDTs. This
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technique is especially advantageous for poor water soluble drugs. Other advantages
of this technology include fast disintegrate/dissolution of nanoparticles leading to
increased absorption and hence higher bioavailability and reduction in dose, cost
effective manufacturing process, conventional packaging due to exceptional durability
and wide range of doses (up to 200 mg of drug per unit).
1.3. Superdisintegrants (www.pharmainfo.net)
A disintegrant helps the tablet to break up into smaller piecesupon contact with
aqueous solution. Fast disintegrate ofa tablet matrix in the oral cavity facilitates
swallowing andincreases the surface area of the tablet particles, which enhancesthe
rate of absorption of the active ingredient to achieve the desired therapeutic effect.
Every marketed tablet has a certainlevel of disintegrant and it is important to
investigate whichand how much disintegrant is necessary for a given
tabletformulation.Disintegrate starts when a small amount of water or salivacontacts
the dosage form (wetting) and penetrates the tabletmatrix by capillary action.
Therefore, the material properties ofpharmaceutical excipients and also the matrix
structure includingpore size and distribution need to be considered for
successfulformulation development. Since most disintegrants swell to someextent,
swelling pressure is generally considered the main factorfor tablet disintegrate.
Disintegrants or superdisintegrantswith efficient disintegrating properties at relatively
low levels can be used in the formulation of MDTs. They are generally added ata level
of 1–10% (w/w%).
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Disintegrate efficiency is based on the force-equivalentconcept (the combined
measurement of swelling forcedevelopment and amount of water absorption).
Forceequivalence expresses the capability of a disintegrant totransform absorbed water
into swelling (or disintegrating) force. The optimization of tablet disintegrate is
commonlydone by mean of the disintegrate critical concentration.Below this
concentration the tablet disintegrate time isinversely proportional to the disintegrant
concentration.Above the critical concentration, the disintegrate timeremains
approximately constant or even increased.One of the most desirable propertiesof
disintegrants is rapid swelling without an accompanyingviscosity increase (no gel
formation), because high viscosity onthe surface of the tablet will hinder water
penetration into thetablet matrix to slow disintegrate.
There are a lot of disintegrants and superdisintegrants onthe market and most
of them can be considered for use in MDTs.Typical examples includes crospovidone
(crosslinked PVP),croscarmellose (crosslinked cellulose), sodium starch glycolate.
(crosslinked starch), and low-substituted hydroxypropylcellulose. Crospovidone is a
synthetic and water insolublecrosslinked homopolymer with the chemical structure of
N-vinyl-2-pyrrolidone. A unique one-step polymerizationprocess known as
‘‘popcorn’’ polymerization is used to synthesize crospovidone polymers. Crosslinking
chemically‘‘entangles’’ the polymer chains and is a major determinant of theproduct’s
properties. This process results in a porous structurewith densely crosslinked polymers
and a morphology thatrapidly wicks liquids into the particle to enhance swelling
anddisintegrate. Crospovidone polymers are non-ionic so theirdisintegrate properties
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are independent of pH changes in thegastrointestinal tract. Moreover, they do not form
gels.
Disintegrants are usually waterinsoluble materials that swell on contact with
moisture, thereforethe addition of excess disintegrant can lead to grittiness aftertablet
disintegrate. The appropriate disintegrant and disintegrantquantity should be carefully
investigated for a given MDT formulation.The particle size distribution of Kollidon
CL and Polyplasdone XL is similar. However, bulk and tappeddensities of the both are
significantly different due to thesmoother surface of Kollidon CL or the porous
structure of Polyplasdone XL. Kollidons CL-F and CL-SF have lower bulkdensities
than that of Polyplasdone XL because of their smallerparticle sizes. Promojel has the
highest bulk and tapped densitiesand Ac-Di-Sol is in between Kollidon CL and
Primojel. Selection of the right disintegrant depends on the formulationapplication and
preparation procedure. For example, when MDTs are prepared using lactose as a
diluent, invivo disintegratetime is dependent on the type of disintegrant.
Crospovidone can work as an efficient disintegrant with fast swelling
properties. When mannitol and crospovidone were formulated by a direct compression
method, the effects of the amount of mannitol and crospovidone as well as the
compression force on the characteristics of the tablet were investigated. An optimum
tablet formulation, containing 34% mannitol and 13% crospovidone, was
recommended and provided a short wetting time of 17 s and a sufficient crushing
strength of 40 N. MDTs were prepared by direct compression using microcrystalline
cellulose (MCC) and low-substituted hydroxypropyl cellulose (L-HPC) as
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disintegrants. It was found that the ratios of the two disintegrants MCC: L-HPC in the
range of 8: 2 to 9: 1 showed the shortest disintegrate times.On the other hand, poly
(acrylic acid) superporous hydrogel (SPH) microparticles were reported to be a super-
disintegrant having a unique porous structure and they were added as a wicking agent
to decrease disintegrate time.
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1.3.1. Commonly used superdisintegrants: (Suresh Bandari, 2010)
Table 1.1: Commonly Employed Superdisintegrants in Mouth Dissolving
Tablets
Superdisintegrant Nature Particle size Mechanism
Crospovidone Crosslinked
homopolymer of N-
vinyl-2-pyrrolidone
Particle size-
100µm
Both swelling and
wicking
Croscarmellose
sodium
Cross-linked form
of sodium CMC
Insoluble in water.
Particle size 200
mesh
Swelling
Sodium starch
Glycolate
Crosslinked low
substituted
carboxymethyl
ether of poly-
glucopyranose
Insoluble in water.
Particle size 140
mesh
Water uptake
followed by rapid
and enormous
swelling
Acrylic acid
derivatives
Poly(acrylic acid)
super porous
hydrogel
Insoluble in
organic solvents,
disperses in cold
water
Wicking action
Effervescent
mixture
Citric acid,tartaric
acid,sodium
bicarbonate,sodium
salt of alginic acid
Crystalline nature Effervescence
Sodium alginate Sodium salt of
alginic acid
Slowly soluble in
water, hygroscopic
in nature
Swelling
NS-300 Carboxy methyl
cellulose (CMC)
Particle size 106
µm
Wicking type
ECG-505 Calcium salt of
CMC
Particle size
106µm
Swelling type
L-HPC Low hydroxyl
propyl cellulose
Particle size
106µm
Both swelling and
wicking
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1.4. Various mechanism of tablet disintegrate (Abhishek Gupta et al.,2010)
The tablet breaks into primary particles by one or more of the mechanisms
listed     below
 By capillary action
 By swelling
 Because of heat of wetting
 Due to disintegrating particle/particle repulsive forces
 Due to deformation
 Due to release of gases
 By enzymatic action
Figure 1.2: Conceptual design of tablet Disintegrate
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Figure 1.3:Mechanism of superdisintegrants by swelling
Ascending order of highest swelling capacity of superdisintegrants
CCS>CP>SSG (Dhanyakumar D. C., 2010)
Figure 1.4:Mechanism of tablet disintegrate
1.4.1. By capillary action
Disintegrate by capillary action is always the first step. When we put the tablet
into suitable aqueous medium, the medium penetrates into the tablet and replaces the
air adsorbed on the particles, which weakens the intermolecular bond and breaks the
tablet into fine  particles.
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Figure 1.5: Disintegrate due to capillary action
1.4.2. By swelling:
Perhaps the most widely accepted general mechanism of action for tablet
disintegrate is swelling Tablets with high porosity show poor disintegrate due to lack
of adequate swelling force. On the other hand, sufficient swelling force is exerted in
the tablet with low porosity. It is worthwhile to note that if the packing fraction is very
high, fluid is unable to penetrate in the tablet and disintegrate is again slows down.
Figure 1.6: Disintegrate due to swelling and wicking
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1.4.3. Because of heat of wetting (air expansion)
When disintegrants with exothermic properties gets wetted, localized stress is
generated due to capillary air expansion, which helps in disintegrate of tablet.
1.4.4. Due to disintegrating particle/particle repulsive forces
Another mechanism of disintegrate attempts to explain the swelling of tablet
made with ‘non-swellable’ disintegrants. Guyot-Hermann has proposed a particle
repulsion theory based on the observation that non swelling particles also cause
disintegrate of tablets.
1.4.5. Due to deformation and repulsion
Hess had proved that during tablet compression, disintegrated particles get
deformed and these deformed particles get into their normal structure when they come
in contact with aqueous media or water. Occasionally, the swelling capacity of starch
was improved when granules were extensively deformed during compression. This
increase in size of the deformed particles produces a break up of the tablet.
Figure 1.7: Disintegrate by deformation and repulsion
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1.4.6. Due to release of gases
Carbon dioxide released within tablets on wetting due to interaction between
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates due
to generation of pressure within the tablet. As these disintegrants are highly sensitive
to small changes in humidity level and temperature, strict control of environment is
required during manufacturing of the tablets. The effervescent blend is either added
immediately prior to compression or can be added in to two separate fraction of
formulation.
1.4.7. By enzymatic reaction
Table 1.2: Disintegrating Enzymes
Enzymes Binder
Amylase Starch
Protease Gelatin
Cellulase Cellulose and it’s derivatives
Invertase Sucrose
Here, enzymes presents in the body act as disintegrants. These enzymes destroy the
binding action of binder and helps in disintegrate.
1.5. Strategies of Taste Masking: (Roop K.Khar, 2001)
Taste is one of the most important parameters governing patient compliance.
Undesirable taste is one of several important formulation problems that are
encountered with certain drugs. Four fundamental sensations of taste have been
described:
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 Sweet and salty, mainly at the tip.
 Sour, at the sides.
 Bitter, at the back.
Taste masking is defined as a perceived reduction of an undesirable taste that
would otherwise exist. Various techniques available for masking bitter taste of drugs
include taste masking with ingredients such as flavors, sweeteners, and amino acids;
taste masking by polymer coating; taste masking by conventional granulation; taste
masking with ion-exchange resins; taste masking by spray congealing with lipids; taste
masking by formation of inclusion complexes with cyclodextrins; taste masking by the
freeze-drying process; taste masking by making multiple emulsions; and taste masking
with gelatin, gelatinized starch, liposomes, lecithins or lecithin-like substances,
surfactants, salts, or polymeric membranes.
1.5.1. Taste Masking with Flavors, Sweeteners, and Amino Acids
This technique is the foremost and the simplest approach for taste masking,
especially in the case of pediatric formulations, chewable tablets, and liquid
formulations. But this approach is not very successful for highly bitter and highly
water soluble drugs. Artificial sweeteners and flavors are generally being used along
with other taste-masking techniques to improve the efficiency of these techniques.
Aspartame is used as a prominent sweetener in providing bitterness reduction. A very
small concentration (0.8%) is effective in reducing the bitterness of 25%
acetaminophen. Starch, lactose, and mannitol have also exhibited taste-masking
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properties of caffeine. Anticholesterolemic saponin-containing foods, beverages, and
pharmaceuticals are supplemented with amino acids (such as glycine and alanine) and
flavors for bitterness control.
1.5.2. Taste Masking with Lipophilic Vehicles
 Lipids:
Oils, surfactants, polyalcohols, and lipids effectively increase the
viscosity in the mouth and coat the taste buds, and therefore they are potential taste
masking agents. Guaifenesin has improved taste when mixed with carnauba wax and
magnesium aluminium silicate and then melt-granulated.
 Lecithin and Lecithin-like Substances:
Formulations with a large excess of lecithin or lecithin-like substances are
claimed to control bitter taste in pharmaceuticals. Magnesium aluminum silicate with
soybean lecithin is used to mask the unpleasant taste of talampicillin Hydrochloride.
The drug is dissolved in or dispersed into an organic solvent such as chloroform.
Lecithin is added to the solution or dispersion of the drug with stirring to give a blend.
The blend is mixed with powdery excipients (e.g., magnesium aluminate metasilicate,
synthetic aluminum silicate, lactose, mannitol, etc.), dried and granulated to give a
taste-masked composition.
1.5.3.Taste Masking by Coating with Hydrophilic Vehicles
This is the simplest and most feasible option to achieve taste masking. The
coating acts as a physical barrier to the drug particles, thereby minimizing interaction
between the drug and taste buds. Coating of chewable tablets provides excellent taste
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masking while still providing acceptable bioavailability. A specialized technique, i.e.,
micro emulsion technology, has been used for taste masking of powders, chewable
tablets, and liquid suspensions.
1.5.4. Carbohydrates (Cellulose)
The taste of orally administered drugs can be masked by coating the drug with
carbohydrates. Bitter solid drugs such as pinaverium bromide, a spasmolytic, has no
bitter taste when formulated in an organoleptically acceptable manner by polymer
coating with a mixture of cellulose or shellac and a second film forming polymer
soluble at pH less than 5.
1.5.5. Taste Masking by Inclusion Complexation
In inclusion complex formation, the drug molecule fits into the cavity of a
complexing agent, i.e., the host molecule, forming a stable complex. The complexing
agent is capable of masking the bitter taste of drug by either decreasing its oral
solubility on ingestion or decreasing the amount of drug particles exposed to taste
buds, thereby reducing the perception of bitter taste. This method is most suitable only
for low dose drugs. Vander Waals forces are mainly involved in inclusion complexes.
The suppression of bitter taste by cyclodextrin was in increasing order of alpha,
gamma, and beta cyclodextrin. β-cyclodextrin is the most widely used complexing
agent for inclusion type complexes. It is a sweet, nontoxic, cyclic oligosaccharide
obtained from starch.
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1.5.6. Solid Dispersion System
Solid dispersion have been defined as dispersion of one or more active
ingredients in an inert carrier or matrix at solid state prepared by melting (fusion)
solvent or melting solvent method. Solid dispersion is also called as co precipitates for
those preparation obtained by solvent method. Solid dispersion of drug with the help
of polymers, sugar, or other suitable agents, is very useful for taste masking. The bitter
taste of dimenhydrinate can be masked by preparing the solid dispersion of the drug
with polyvinyl acetate phthalate. Solid dispersions using insoluble matrices or bland
matrices may be used to mask the bitter taste of drugs. Also using them as absorbents
on various carriers may increase the stability of certain drugs.
1.5.7. Prodrugs
A prodrug is a chemically modified inert drug precursor, which upon
biotransformation liberates the pharmacologically active parent drug. The
alkyloxyalkyl carbonates of the clarithromycin 2’ position have remarkably alleviated
bitterness and improved bioavailability when administered orally.Tasteless/bitter le ss
prodrugs of opioid analgesics and antagonists were formulated for improved buccal
delivery. Tasteless prodrugs of nalbuphine Hydrochloride, naltrexone, naloxone,
oxymorphone Hydrochloride, butorphanonol, and levallorphan were synthesized for
buccal administration to improve bioavailability relative to that of oral dosing without
the characteristic bitter taste.
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1.5.8. Ion Exchange Resin
Another popular approach in the development of taste masking is based on ion
exchange resin. Ion exchange resins are solid and suitably insoluble high molecular
weight polyelectrolytes that can exchange their mobile ions of equal charge with the
surrounding medium. The resulting ion exchange is reversible and stiochiometric with
the displacement of one ionic species by another.
Ion exchange resins can be classified into four major groups
 Strong acid cation-exchange resin.
 Weak acid cation-exchange resin.
 Strong base anion-exchange resin.
 Weak base anion-exchange resin.
Strong acid cation resins (sulfonated styrene di vinyl bezene copolymer
product) function throughout the entire pH range and can be used for masking the taste
of basic drugs. Weak acid cation exchange resins function at pH values above 6.0.
Similarly, strong base anion-exchange resins function throughout the entire pH range
and can be used for masking the taste of acidic drugs, while the weak base anion
exchange resins function well below pH 7.0 Synthetic ion exchange resin have been
used in pharmacy and medicine for taste masking or controlled release of drug as early
as 1950.
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1.5.9. Miscellaneous Taste-Masking Approaches
1.5.9.1. By Effervescent Agent
Effervescent agents have been shown to be useful and advantageous for oral
administration of drugs and have also been employed for use as taste-masking agents
for dosage forms that are not dissolved in water prior to administration. A chewing
gum composition of bitter medicament(s) was formulated to supply the medicament(s)
to the oral cavity for local application or for buccal absorption. It comprises a chewing
gum base, an orally administrable medicament, a taste masking generator of carbon
dioxide, and optionally a taste bud desensitizing composition (e.g., oral anesthetics
such as benzocaine and spilanthol) and other nonactive materials, such as sweeteners,
flavoring components, and fillers. Recently, effervescent tablets of fentanyl and
prochlorperazine were developed to supply these drugs to the oral cavity for buccal,
sublingual, and gingival absorption.
1.5.9.2. Salt Preparation
Adding alkaline metal bicarbonate such as sodium bicarbonate masks the
unpleasant taste of water-soluble ibuprofen salts in aqueous solution. The bitter taste
of caffeine may be masked by formulating it as a carbonated oral solid preparation
using sodium bicarbonate, ascorbic acid, citric acid, and tartaric acid. Magnesium
aspirin tablets are rendered tasteless by preparing magnesium salts of aspirin.
Penicillin prepared as N, N’-dibenzylethylene-diamine diacetate salts or N, N’-bis
(deyhdroabiety) ethylenediamine salts is tasteless. Bitterness-reduced antitussive and
expectorant compositions (tablets) of dihydrocodeine phosphate, DL-methylephedrine
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Hydrochloride, and D-chlorpheniramine maleate contain magnesium salts, sweeteners,
starch, and cellulose.
1.5.9.3. Freeze Drying Process
This method is used to develop fast-dissolving oral technologies such as Zydis
and Lyoc technology. Zydis is a tablet-shaped dosage form that spontaneously
disintegrates in the mouth in seconds. This is due to the high porosity produced by the
freeze drying process. The Zydis process requires the active ingredient to be dissolved
or suspended in an aqueous solution of water soluble structure formers. The resultant
mixture is then poured into the preformed blister pockets of a laminate film and freeze
dried. The two most commonly used structural excipients are gelatin and mannitol,
although other suitable excipients can be used (e.g., starches, gums, etc.). This process
is ideally suited to low solubility drugs as these are more readily freeze dried. Taste is
very important for this type of dosage form and it is possible to produce palatable
formulations by using artificial sweeteners (e.g., aspartame) and conventional flavors.
Various drugs have been taste-masked by Zydis technology. These are lorazepam
(Wyeth), piroxicam (Pfizer), loperamide (Janssen), ondansetron (Glaxo Wellcome),
rizatriptan (Merck), loratadine (Schering Plough), olanzapine (Eli Lilly), selegiline
(Elan), scopolamine/ chlorpheniramine (Taisho), etc.
1.6. Taste Assessment
Taste assessment one of the important quality control parameters for
evaluation of taste masked formulation .Drug or formulation can be assessed using in
vivo and in vitro method of taste evaluation parameters.
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1.6.1. In vitro approaches taste assessment
1.6.1.1. In vitro drug release studies
Pharmacopoeial release studies have been modified by altering the chemical
composition of the dissolution media (e.g. artificial saliva) and reducing the size of the
basket screen size (screen size< 0.381 mm square opening) to prevent particles forms
escaping. Taste masking is achieved when, in the early time points from 0-5 minutes
the drugs substances in the dissolution medium is either not detected or amount is
below the threshold for identifying its taste. Drug can be analyzed either
spectrophotometrically or using HPLC. Of these HPLC is generally preferred
especially when testing is performed in the presences of UV-absorbing component,
such as flavorings and sweetener. A novel invivo buckle dissolution testing apparatus
and method for the assessment of taste masking in oral dosages forms have recently
been invented. The apparatus consists of a single, stirred, flow-through filtration cell
including a dip tube designed to remove fine solid particles. Simulated saliva is used
as the dissolution medium. The filtrated solution is removed from the apparatus
continuously and used to analyze the dissolve drug.
1.6.1.2. Voltramettric electronic tongue
The Voltramettric electronic tongue developed by s-*sense consistent of four
working metal electrode made of gold, platinum, iridium and rhodium an Ag/AgCl
references and a stainless steel counter electrode. A relay box enables the working
electrode to be connected consecutively, to form four standards three-electrode
configurations. The potentially pulse are applied by a potentiostat which is controlled
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by a personnel computer. The PC used to set and control the pulse, measure and store
current response, and to operate the relay box.
1.6.1.3. Electronic tongue
The electronic tongue initially developed by the University of Taxes consists
of light sources, a sensors array and detector. The light sources shines onto chemically
adapted polymer beads arranged on a small silicon wafer, which is known as a sensors
chip the beads change is color on the basis of the presences and quality of specific
chemical. The change is color is capture by a digital camera and the resulting signal
converted into data using video capture board and a computer.
1.6.2. In vivo approaches for taste assessment
In vivo studies, stimuli are applied on to the tongue of either human or
animals.
1.6.2.1. Human taste panel studies
Human taste panel studies evaluated tastant (food, chemical, drug and so on)
by estimating the gustatory sensation response in healthy human volunteers within
well-controlled process. Such studies are there for also known as physiological
evaluation, gustatory sensation testes or taste trials. They are sensitively measured of
taste and are spastically designed to minimize bias and response within and between
human volunteers. Well-established methodology for performing sensory analysis can
be broadly divided into five types, namely discrimination taste. Scaling taste, experts
testers, affective taste and descriptive methods and have been excellency discussed.
Volunteers asses the taste quality and intensity of standard are taste stimuli on
LORATADINE MDT – AS NOVEL APPROACH INTRODUCTION
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 39
different adjective scales including various properties of the sample, such as overall
intensity, sweet, odor, bitter, metallic, cooling, hot, spicy, anesthetic, astringent etc.
Each adjective can be rated as intensity rated on the scale zero to four a perhaps even
up to nine points on the provided score rates.
1.6.2.2. Animal preference testes
Bottle performance and condition taste aversion taste are used for taste for
determining taste preference and concentration-response properties of tastant by
animal  3 and 4 rats, mice, cats and dogs can be used for the potentiometrically e-
tongue, incorporating and array of artificial lipid-polymer membranes as a fingerprint
devices, has been developed as a promising tool for use in the quality control of
phytomedicines. The miniaturization of taste sensors is particularly interest for the
food and pharmaceutical industries. A portable low-cost sensing system has been
made that interfaces to a Voltramettric electronic tongue sensors. Screen-printing
technologies have been used to develop disposable taste sensors.
1.7. Patented Technology for Mouth Dissolving Tablets
(Bandari Suresh, 2008 ; Brahmeshwar Mishra, 2009)
1.7.1. Zydus Technology
Zydus formulation is a unique freeze dried tablet in which drug is physically
entrapped or dissolved within the matrix of fast dissolving carrier material. When
Zydus units are put into the mouth, the freeze-dried structure disintegrates
instantaneously and does not required water to aid swallowing. The Zydus matrix is
composing of many materials designing to achieve a number of objectives. To impart
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strength and resilience during handling, polymer such as gelatin, dextran or alginates
are incorporated. These form a glossy amorphous structure, which impart strength.
To obtain crystallinity, elegance and hardness, saccharides such as mannitol or
sorbitol are incorporated. Water is used in the manufacturing process to ensure
production of porous units to achieve rapid disintegrate while various gums are used to
prevent sedimentation of dispersed drug particles in the manufacturing process.
Collapse protectants such as glycine prevent the shrinkage of Zydus units during
freeze drying process or long term storage. Zydus products are packed in blister packs
to protect formulation from moisture in the environment.
1.7.2. Durasolv Technology
Durasolv is the patented technology of CIMA labs. The tablets made by this
technology consist of drug, filler and lubricant. Tablets are prepared by using
conventional tableting equipment and have good rigidity. These can be packaged into
conventional packaging system like blisters. Durasolv is an appropriate technology for
product requiring lowamount of active ingredients.
1.7.3. Orasolv Technology
CIMA labs have developed orasolv Technology. In this system active
medicament is taste masked. It also contain effervescent disintegrating agent. Tablets
are made by direct compression technique atlow compression force in order to
minimize oral dissolution time. Conventional blenders and tablet machine is used to
produce the tablets. The tablets produced are soft and friable.
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1.7.4. Flash Dose Technology
Flash dose technology has been patented by Ethypharm France. Nurofen
meltlet, a new form of Ibuprofen as melt in mouth tablets prepared using flashdose
technology is the first commercial product launched by Biovail Corporation. Flash
dose tablets consist of self- binding shear form matrix termed as “Floss Shear” form
matrices are prepared by flash heat processing. This technology is also called as
Cotton Candy Process.
1.7.5. Wowtab Technology
Wowtab technology is patented by Yamanouchi Pharmaceutical Co.WOW
means “Without Water”. In this process, combination of low mould ability saccharides
and high mould ability saccharides is used to obtain a rapidly melting strong tablet.
The active ingredient is mixed with a low mould ability saccharide and granulated
with a high mould ability saccharide and compressed into tablet.
1.7.6. Flashtab Technology
Prographarm laboratory have patented the flashtab technology. Tablet prepared
by this system consist of active ingredient in the form of micro crystals. Drug micro
granules may be prepared by using the conventional techniques like coacervation,
micro encapsulation an dextrusion - spheronisation. All the processing utilized
conventional tabletting technology.
LORATADINE MDT – AS NOVEL APPROACH INTRODUCTION
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 42
1.8. The Following Category of Drugs Can be Formulated As Fast Dissolving
Dosage Forms. (www.pharmainfo.net)
There are no particular limitations as long as it is a substance which is used as
a pharmaceutical active ingredient.
Anti-epileptics, Analgesics, Anthelmintics,  Anti-Arrhythmic agents, Anti-
bacterial agents, Anti-coagulants, Anti-depressants, Anti-diabetics, Anti-gout, Anti-
hypertensive Agents, Anti-malarial agents, Anti-migraine agents, Anti-muscarinic
agents, Anti-neoplastic agents, Immunosuppressants, Anti-protazoal agents, Anti-
thyroid agents, β-blockers, Cardiac inotropic agents, Corticosteroids, Diuretics, Anti-
parkinsonian agents, Gastro intestinal agents, H1-receptor antagonists, Lipid
regulating agent, Neuro -muscular agents, Nitrates and other anti-anginal agents,
Nutritional agents, Opioid analgesics and  Sex hormone.
1.8.1. Patient Counseling In Effective Use of Fast Dissolving Tablets
ODT developed offers significant advantages for various groups of patients,
but the majority of patients receiving ODT have little understanding of this novel
dosage form. Patients receiving ODT may be surprised when tablets begin to
disintegrate/dissolve in mouth. As pharmacists are ideal persons to know about the
recent technologies, thus have opportunity to educate the patient for effective
treatment. Counseling of patients about this dosage form can avoid any confusion and
misunderstanding in taking ODT. Patient information that needs to be provided
includes
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Storage of this dosage form as some of ODT developed may not have sufficient
mechanical strength, which needs to be handled carefully.
Patients with Siogren's syndrome or dryness of mouth or who take anti
cholinergic drugs may not be suitable candidates for administering ODT. Although no
water is required to allow drug to disperse quickly and efficiently but decreased
volume of saliva may slow the rate of disintegrate/dissolution and may reduce the
bioavailability of the product
Patients need to be clearly told about the difference between effervescent and
ODT. Some of technologies use effervescence, which experience a pleasing tingling
effect on the tongue.
Although chewable tablets are available in market and patient need to be
counseled about differences between chewable and ODT tablets. This ODT can be
used easily in children who have lost their primary teeth and in geriatric patients who
have lost their teeth permanently.
Patients may mistake fast-dissolving/disintegrating for effervescent tablets.
Pharmacists may wish to stress the difference between the use of quick-dissolving and
effervescent tablets. The Cima technologies, OraSolv and DuraSolv, use slight
effervescence. Patients may experience a pleasant tingling on the tongue with OraSolv
and DuraSolv.
With the pharmacists counseling, intervention and assistance about ODT, all
patients receiving this novel dosage form could be more properly and effectively
treated with greater convenience.
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Table 1.3: List of Commercially Available MDTs (www.pharmpedia.com)
Trade Name Active Drug Manufacturer
Feldene Fast, Melt Piroxicam Pfizer Inbc., NY,USA
Claritin Redi Tab Loratidine Schering  PloughCorp.,Kenilworth,USA
Mazalit MTL Rizatriptan Merckasnd Co., NJ, USA
Zyprexia Olanzapine Eli Lilly, Induanapolis, USA
Zofran ODT Ondansetron Glaxo wellcome, Middleselx, UK
Zoming – ZMT Zolmitriptan AstraZeneca, Wilmington, USA
Zeplar TM Selegilline Amarin Corp., London, UK
Tempra Quiclets Acetaminophen Bristol Myers Squibb, NY ,USA
Febrectol Paracetamol Prographarm. Chateauneuf, France
Nimulid MDT Nimesulide Panacea Biotech, New-Delhi, India
Torrox MT Rofecoxib Torrent Pharamceuticals, Ahmedabad
Olanex Istab Olanzapine Ranbaxy Labs Ltd., New-Delhi, India
Romilast Montelukast Ranbaxy Labs Ltd., New-Delhi, India
Relivia Flash dose Tramadol HCl Fuisz Technology, Ltd, India
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2. AIM AND OBJECTIVE
AIM
Aim of present study is to formulate Loratadine mouth dissolving tablets by using
different super disintegrants and evaluating its characteristics.
OBJECTIVE
The objective of present study is
1.The investigation was undertaken with a view to develop fast dissolving tablets to get
the quick onset of action in treatment of a suddenly arising allergic reactions.
2. To evaluate the effect of three different superdisintegrants on disintegrate parameter
and the wetting properties of the tablets.
3.For to inhibit and numb the test of Loratadine by using sensory approach method.
4. To avoid first pass metabolism by giving absorption of Loratadine from oral cavity,
pharynx and oesophagus regions.
5. To develop mouth dissolving drug delivery system by simple and cost effective
technique.
This mouth dissolving tablet of Loratadine will disintegrate rapidly in the patient
mouth without need of water or chewing and released its drug content instantaneously
with rapid disintegrate/dissolution, quick absorption from oral cavity, pharynx and
esophagus in turn shows immediate relief. So this dosage form is more comfortable for
paediatric, geriatric patients.
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Thus, mouth dissolving tablets of Loratadine truly serve as Orodispersible Drug Delivery
System because of its convenient nature.
Plan of work
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The study was planned to carry out as follows,
1 Literature review
2 Selection of drug and excipients
3. Procurement of drug, Polymer and other excipients
4. Experimental work
A Preformulation study
Identification of drug
 By FTIR spectroscopy
 By Melting point
Physicochemical parameter
 Organoleptic properties
 Solubility profile
 Loss on drying
Analytical methods
 Determination of absorption maxima.
 Development  of standard curve of Loratadine
 Determination of % purity of drug
Determination of  drug polimer compatibility
 By FTIR spectroscopy
 By DSC thermal analysis
3. PLAN OF WORK
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5. Formultion and characterization of powder blend
 Sodium starch glycollate (Explotab)
 Croscarmellose Sodium (Ac-Di-sol)
 Crospovidone (polyplasdone)
6. Evaluation of powder mixed blend of drug and excipients
 Angle of Repose
 Bulk Density
 Tapped Density
 Compressibility index
 Hausner ratio
7. Formulation and Compression of Mouth Dissolving tablet by direct compression
method
8. Evaluation of compressed MD tablets
 Appearance
 Weight variation
 Thickness
 Hardness
 Friability
 Estimation of drug content
 Disintegration time
 Wetting time
LORATADINE MDT – AS NOVEL APPROACH PLAN OF WORK
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 49
 Water absorption ratio
 In-vitro Dissolution studies
9. Stability testing of optimized batch
10. Results and Discussion
11. Summary and Conclusion
12. Future Prospects
13. Bibliography
Literature
Review
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4. LITERATURE REVIEW
Abu Izza et al ., ( 2004 ). The method comprises of combining on active ingredient
with a fast dissolving granulation. The fast dissolving granulation contains a low
melting point compound that melts or softens at or below 37ºC and a water soluble
excepient.
Ahmad I.S., Nafadi M.M., Fatahalla F.A. et al., (2006) Went ahead and formulated
fast dissolving ketoprofen tablets using freeze drying technique in blister).
Chaudhari P.D. et al.,(2005) Carried out formulation and evaluation offast dissolving
tablets of Famotidine by using different superdisintegrates (Ac-di-sol and
Polyplasdone) with varyingconcentrations (2%, 3%, 4% and 5%) The bitter taste of
Famotidinewas masked using Drug .Eudragit E-l00 in different ratios (1:1 –1:10). The
dissolution release rate was found to be 100% in 4minutes.
Cirri M. and Mura P. Developed fast  dissolving tablets of glyburide based on
ternary solid dispersion with poly ethylene 6000 and surfactant . Glyburide a
commonly used anti diabetic and oral hypo Glycemic agent shows very low aqueous
solubility .Dissolution  can represent major rate limiting step to oral absorption and
consequently bio availability of scarcely water soluble, poorly wettable but highly
permeable drugs. These drug are classified as class II compounds according to
Biopharmaceutical classification ( BCS ) system. A simple technicque used to enhance
the dissolution properties of poorly water soluble drugs is the addition of appropriate
surfactant to the formulation. Their findings indicator that simultaneous presence of
surfactant and a hydrophilic polymer gave rise to synergistic effect of their solubility
and wetting properties towards the drug. On the same lines Liu C. and Desai K.G
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made fast dissolving tablets based on enhancement of dissolution rate of valdecoxib
using solid dispersion with poly ethylene glycol 4000.
Devi V.K. et al.,(2006) Carried out formulation of Orodispersible tablets of
fluconazole using two different volatilizable compounds Viz. ammonium chloride and
camphor by Wet Direct Compression method. Best formulations were chosen and
compared with marketed conventional tablets. No significant difference between the
technological properties of the prepared formulations and the marketed tablets.
Ganesh kumar Gudas , Manasa B, et al., (2010) Formulation and evalution of fast
dissolving tablets of  Chlorpromazine HCl an attempt has been made to prepare fast
dissolving tablets of Cholorpromazine HCl in the oral cavity with enhanced dissolution
rate. The tablets was prepared with five superdisintegrants. Eg Sodium starch glycolate
,Crospovidone , Croscarmellose , l-hac, pregelatinised starch. It was concluded that the
fast dissolving tablets with proper hardness, rapidly disintegrating with enhanced
dissolution can be made using selected superdisintegrants.
Gattani S.G. et al., (2009) This study was aimed at development of Ondansetron
Hydrochloride mouth dissolving tablets which can disintegrate or dissolve rapidly
once placed in the oral cavity. This tablet is to combat emesis and nausea.
Hiremath J.G.,et al.,(2004) This article discusses the past and recent approaches and
methodology for bitterness reduction for oral pharmaceuticals. Several
Pharmaceuticals, active agents, numerous food and beverage products and bulking
agents, have unpleasant bitter tasting components. In some cases, the bitter taste is an
undesirable trait of the product or formulations and can considerably affect its
acceptability by consumers. Bitter characteristics found in such system have been
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eliminated or minimized by various known processes, but no universally applicable
technology for bitterness inhibition has been recognized.
Keny R.V., et al., (2010) Mouth disintegrating tablets of rizatriptan benzoate were
prepared using superdisintegrants Crospovidone, carboxymethylcellulose calcium,
indion 414 and indion 234 using the direct compression method. The tablets
disintegrsted in vitro and in vivo within 4 to 7 s and 6 to 19 s, respectively. Almost
90% of drug was released from all formulation within 20 min. The drug release from
the formulations followed first order kinetics. The  formulation containing
combination of crospovidone and indion 234 was found to give the best results.
Abdel Bary A ,Omneya M., et al (2010) Fast dissolving tablets (FDTs) of amlodipine
besylate were prepared by direct-compresion method. Nine formulae having three
subliming agents at three different concentration levels were prepared to assess the
most efficiency and critical concentration level. Twelve formulae having three
subliming agents at the predetermined level and two superdisintegrants and their
critical concentration level and coprocessed superdisintegrants and its critical
concentration level.
Kuchekar B. S., et al,. (2003) Recent advances in Novel Drug Delivery System
(NDDS) aims to enhance safety and efficacy of drug molecule by formulating a
convenient dosage form for administration and achieve better compliance. One such
approach is fast mouth dissolving tablet. Present review article focuses on significance
of mouth dissolving dosage forms and the techniques and technologies available for
their manufacturing.
Kuchekar B.S. et al.,(2004) Carried out formulation of mouth dissolving tablets of
Sumatriptan succinate using super disintegrants like Sodium starch glycollate,
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Carboxy methylcellulose sodium and Treated agar by Direct compression method.
Almost 90% of drugs were released from all formulations within 10 minutes. The
formulation containing combination of sodium starch glycollate and Carboxy methyl
cellulose was found to give the best results.
Kuchekar B. S., et al., (2006) Orodissolving tablets of Promethazine hydrochloride
were prepared using superdisintegrants, sodium starch glycolate and cross carmellose
sodium by direct compression method. The prepared tablets were evaluated for
uniformity of weight, tensile strength, content uniformity, hardness, friability, wetting
time, in vitro and in vivo dispersion time and in vitro drug release.
Lalla J.K. et al.,(2004) Studied the inclusion complex of Rofecoxib with Beta-
cyclodextrin using ball milling technique has been prepared and evaluated. The tablet
shows complete release of Rofecoxib in 12 minutes as compared to 20% drug release
from conventional released marked tablets.
Luca Dobetti, et al., (2001) The demand for fast-melting tablets (FMTs) has been
growing during the last decade, particularly for children and the elderly who have
difficulty swallowing tablets and capsules. These dosage forms are placed are placed
in the mouth, allowed to disperse or dissolve in the saliva, and then swallowed without
the need for water. The advantage of this convenient administration has encouraged
both academia and industry to generate new fast-disintegrating formulations and
technological approaches in this field. This article reviews the latest progress in the
development of FMTs.
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Mallikarjuna Setty C.etal., (2008) In this literature MD tablet was prepared by direct
compression method. Effect of superdisintegrants such as cross carmellose sodium,
sodium starch glycollate, and crospovidone on wetting time, disintegrate time, drug
content, in-vitro release and stability parameters has been studied. It is concluded that
fast dispersible Aceclofenac tablets could be prepared by direct compression using
superdisintegrants.
MishraD.N. et al., (2005) Carried out formulation of rapidly disintegrating tablets of
Valdecoxib using super disintegrants like sodium starch glycollate, Ac-di-sol,
Crospovidone. The poor aqueous solubility of the drug results in variable dissolution
rate hence poor bioavailability. In the present study, an attempt had been made to
prepare fast disintegrating tablets of the drug using various superdisintegrants
following direct compression technique. It was concluded that the fast dissolving
tablets of the poorly soluble drugs can be made by direct compression technique using
selective superdisintegrants showing enhanced dissolution i.e. improved
bioavailability and hence better patient compliance and effective therapy.
Mishra D.N. et al.,(2006) Carried out formulation of rapidly disintegrating tablets of
Meloxicam using super disintegrants like sodium starch glycollate, Ac-di-sol and low
molecular weight HPMC. The disintegrate time in the oral cavity was tested and was
found to be around 1 minute. It was concluded that rapidly disintegrating tablets with
proper hardness rapidly disintegrates in the oral cavity with enhanced dissolution rate.
Modi a., Tayade P. et al., (2006) studied the enhancement of dissolution profile by
solid dispersion technique.
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Mukesh G. et al., (2006) Formulates mouth dissolving tablet of Nimesulide. Granules
containing nimesulide, camphor, crospovidone and lactose were prepared by wet
Direct Compression technique. Camphor was sublimed from the dried granules by
exposure vacuum. The porous granules were then compressed and evaluated. The
result for obtaining a rapidly disintegrating dosage forms, tablets should be prepared
using an optimum concentration of camphor and a higher percentage of crospovidone.
Patil M.B. et al., (2006) Formulated and evaluated ondansetron HCl directly
compressed mouth dissolving tablet.
Popa G. and Gafitanu E. et al., (2000) studied oral disintegrating tablets as a new
modern solid dosage form. FuY and Park K. studied the application of poly acrylic
super porous hydro gel micro particles as a superdisintegrant in fast dissolving tablets.
Direct compression is the easiest way of manufacturing tablets. Super porous hydrogel
has numerous porous connected together to form open channel structure. Water is
absorbed in to dried super porous hydrogel by capillary wetting rather than by
diffusion. It swells fast with the swelling ratio more than 100 times with in minutes.
Fast dissolving tablets prepared by direct compression in the presence of super porous
hydrogel micro particles disintegrate very quickly ( Park ).
Prameela Rani A.,Kanakadurga N. et al., (2010) Formulation and evaluation of
taste smasked oro dispersible tablets of Montelukast sodium. The purpose of this
research was to mask the intensely bitter taste of montelukast sodium adopting
inclusion complex formation array using betacyclodextrin by kneading method.
Through this research work we have formulated and evaluated ODTs (oro dispersible
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tablets) by attending the optimization of taste masked inclusion complex of drug with
β-CD at various ratios.
Roop K. Khar, et al., (2001) Taste is one of the most important parameters governing
patient compliance. Undesirable taste is one of several important formulation
problems that are encountered with certain drugs. Oral administration of bitter drugs
with an acceptable degree of palatability is a key issue for health care providers,
especially for pediatric patients. So, any pharmaceutical formulation with a pleasing
taste would definitely be preferred over a competitor’s product and would translate
into better compliance and therapeutic value for the patient. The desire of improved
palatability in these products has prompted the development of numerous formulations
with improved performance and acceptability. This article reviews the earlier
applications and methodologies of taste masking and discusses the most recent
developments and approaches of bitterness reduction and inhibition for oral
pharmaceuticals.
Sajal Kumar Jha et al., (2006) In present investigation Haloperidol was well
absorbed after oral dose. There is a first pass metabolism leading to a reduced
bioavailability which in need of dosage forms development. Melt-in-mouth tablets of
Haloperidol are prepared by direct compression method using superdisintegrants such
as croscarmellose sodium, sodium starch glycollate, crospovidone. Resultant; various
formulations reveals the improved bioavailability.
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Sammour O.A., Hammaad M.A., Megrap N.A., Zidan A.S. et al., (2006) Carried
out the formulation and optimization of mouth dissolving tablets containing
rofecoxcib.
Seagar. H. et al., ( 1995 ) studied new drug delivery products and , for and process
technology of zydis for preparing fast dissolving tablets. zydis  formulation consists of
drug physically entrapped or dissolved within the matrix of fast dissolving carrier
matriel. Seager studied the matrix characteristics,packaging,moisture pickup
properties etc.and concluded that the overall dissolution rate of water insoluble drug
from Zydis dosage form from the fluids of GIT is similar to that from oral dosage
form and bioavailability of water insoluble substances is equivalent to that of high
quality tablets and hard gelatin capsules.
Shirwailkar A.A. et al., (2004) Formulated Atenolol fast disintegrating tablet using
three superdisintegrants croscarmellose (Ac-di-sol), crospovidone (Polyplasdone) and
sodium starch glycollate. Ac-di-sol proved to be the best among the three and showed
satisfactory results.
Shirwaikar A. et al., (2005) Carried out formulation of fast dissolving tablets of
Granisetron Hydrochloride using super disintegrants by employing Direct
compression method, Formulation containing crospovidone and croscarmellose
sodium displayed shortest disintegrate time compare to other disintegrants.
Shishs and bhatti A. et al., (Aug 2006)Made of fast dissolving tablets of diazepam at
university Dept. of pharm. Sciences, Punjab university Chandigarh.
LORATADINE MDT – AS NOVEL APPROCH LITERATURE REVIEW
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 58
Sreenivas S. A. et al., (2006) Carried out formulation and evaluation of mouth
disintegrating tablets of Ondansetron hydrochloride by direct compression method, by
using disintegrates like crospovidone, croscarmellose sodium, pregelatinized starch,
sodium starch glycolate that 10% disintegrate concentration is suitable for the
preparationof Ondansetron hydrochloride and tablets containing disintegrates
crosspovidone and crosscarmellose sodium are the best.
Van Schaick.et al., (2003 ) Did the pharmacokinetic comparision of fast
disintegrating and conventional tablet formulation of resperidone in healthy volunteers
and found that in healthy subjects , a tablets was equivalent to a single administration
of two 0.5 mg conventional tablet .
Venkatalakshmi R. et al., (2009) Granisetron hydrochloride 200 mg mouth
dissolving tablet was prepared by sodium Starch glycolate, Cros carmellose
sodium,Cros povidone at various concentration and sucralose, aspartame used as
sweetening agent. All the formulation were prepared by direct compression method.
Drug
and
Excipients
profile
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5 DRUG AND EXCIPIENTS PROFILE
5.1. DRUG PROFILE
(Moffat A.C, 2004;USP 2009; Indian Pharmacopoeia, 2007;www.pharmpedia.com;
CIMS,2009; www.drugs.com)
Synonyms:
Loratadina [Spanish]
Loratadinum [latin]
Proprietary names:
Aerotina, alarin, alavert, biloina, claritin-d, loritine, lorfast, loraver.
Chemical structure:
Cl
N
N
O
CH3
O
Molecular formula: C22H23ClN2O2
Molecular weight: 382.88
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Iupac name:
Ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-2-
ylidene}piperidine-1-carboxylate
Indications :
A self-medication that is used alone or in combination with pseudoephedrine sulfate
for the symptomatic relief of seasonal allergic rhinitis. Also used for the symptomatic relief
of pruritus, erythema, and urticaria associated with chronic idiopathic urticaria in patients
(not for children under 6 unless directed by a clincian).
Appearance:
A white or almost white, characteristic, fine powder.
Solubility:
Freely soluble in acetone, Chloroform,methanol,toluene,insoluble in water.
Melting point:
134-136ºC
Metabolism:
Hepatic
Toxicity:
somnolence, tachycardia, and headache LD50=mg/kg (orally in rat)
Serious side effects:
 fast or uneven heart rate;
 feeling like you might pass out;
 jaundice (yellowing of your skin or eyes); or
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 seizures (convulsions).
Less serious side effects may include:
 headache;
 nervousness;
 feeling tired .
Bioavailability:
Available about 50 to 60%. Depends partly on dosage form. Bioavailability of mouth
dissolving tablet is relatively more, than other oral dosage forms.
Half–life:
8.4 hours
Volume of distribution:
4.5 to 8 L/kg
Clearance:
The total oral clearance from plasma is 6 to 10mL/min/h
Protein binding:
97-99%
Dose:
10 mg to 50 mg daily with a maximum of 300mg daily in divided doses.
Pharmacodynamic:
Loratadine is a long acting second generation antihistamine that is similar in
structure to cyproheptadine and azatadine. The pharmacology of loratadine is similar to
other antihistamines, but unlike other H1-blockers, loratidine is shown to exhibit
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competitive, specific, and selective antagonism of H1 receptors. The exact mechanism of
this interaction is unknown, but disposition of the drug suggests that loratadine's prolonged
antagonism of histamine may be due to the drug's slow dissociation from the receptor or the
formation of the active metabolite, desloratadine. Loratadine does not penetrate the CNS
effectively and has a low affinity for CNS H1-receptors.
Mechanism of Action:
Loratadine competes with free histamine and exhibits specific, selective peripheral
H1 antagonistic activity. This blocks the action of endogenous histamine, which
subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion,
watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors
and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine
also appears to suppress the release of histamine and leukotrienes from animal mast cells,
and the release of leukotrienes from human lung fragments, although the clinical importance
of this is unknown.
Pharmacology and Uses:
Loratadine is long acting peripheral H1-receptor antagonist. It is mainly used as
antihistaminic drug.
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5.2. EXCIPIENT PROFILES
I. SODIUM STARCH GLYCOLLATE
(Raymond C. Rowe, 2003)
Nonproprietary names:
BP Sodium starch glycollate; PhEur Carboxymethylamylum natricum; USPNF
Sodium starch glycollate.
Synonyms:
Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; starch
carboxymethyl ether, sodium salt.
Chemical name:
Sodium carboxymethyl starch
Empirical formula and molecular weight:
The USPNF 23 states that sodium starch glycollate is the sodium salt of a
carboxymethyl ether of starch, containing 2.8 to 4.2% sodium.
The PhEur 2005 describes three types of material Types A and B occurs as the sodium salt
ofa cross-linked partly O-carboxymethylated potato starch, containing 2.8 to 4.2% and 2.0
to 3.4%of sodium respectively. Type C is the sodium salt of a cross-linked by physical
dehydration, partly O-carboxymethylated starch containing 2.8–5.0% sodium. The JP,
PhEur and USPNF monographs have been Harmonized for Type A and Type B variants
Sodium starch glycollate may be characterized by the degree of substitution and cross
linking. The molecular weight is typically 5 × 105 - 1 × 106.
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Structural formula:
Functional category:
Pharmaceutical excipients, tablet and capsule disintegrate.
Applications in pharmaceutical formulation or technology:
Sodium starch glycollate is widely used in oral pharmaceuticals as a disintegrate in
capsule and tablet formulations . It is commonly used in tablets prepared by either direct
compression or wet-granulation processes. The usual concentration employed in a
formulation is between 2% and 8%, with the optimum concentration about 4%, although in
many cases 2% is sufficient. Disintegrate occurs by rapid uptake of water followed by rapid
and enormous swelling. Although the effectiveness of many disintegrates is affected by the
presence of hydrophobic excipients such as lubricants, the disintegrate efficiency of sodium
starch glycollate is unimpaired. Increasing the tablet compression pressure also appears to
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have no effect on disintegrate time. Sodium starch glycollate has also been investigated for
use as a suspending vehicle.
Description:
Sodium starch glycollate is a white to off-white, odorless, tasteless, free-flowing
powder. The PhEur 2005 states that it consists of oval or spherical granules, 30 - 100 μm in
diameter, with some less-spherical granules ranging from 10 - 35 μm in diameter.
Typical properties
Acidity/alkalinity:
pH = 3.0–5.0 or pH = 5.5–7.5 for a 3.3% w/v aqueous dispersion.
Ash:
= –15% for Explotab
Density (bulk):
0.756 g/cm3; 0.75 g/cm3for Explotab; 0.81 g/cm3 for Primojel; 0.67 g/cm3 for Tablo.
Density (tapped):
0.945 g/cm3; 0.88 g/cm3, for Explotab.
Density (true):
1.443 g/cm3; 1.51 g/cm3 for Explotab.
Melting point:
Does not melt, but chars at approximately 200°C.
Particle size distribution:
100% of particles less than 106 μ cm in size. Average particle size is 35–55 μ cm for
Explotab.
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Solubility:
Sparingly soluble in ethanol,  practically insoluble in water. At a concentration of
2%w/v sodium starch glycollate disperses in cold water and settles in the form of a highly
hydrated layer.
Specific surface area:
0.24 m2/g; 0.202 m2/g for Explotab;
Swelling capacity:
In water, sodium starch glycollate swells to up to 300 times its volume.
Viscosity (dynamic):
=¼200 m Pa s (200 cP) for a 4% w/v aqueous dispersion. Viscosity is 4.26 m Pa s
for a 2% w/v aqueous dispersion.
Stability and storage conditions:
Tablets prepared with sodium starch glycollate have good storage properties.
Sodium starch glycollate is stable and should be stored in a well-closed container in order to
protect it from wide variations of humidity and temperature, which may cause caking. The
physical properties of sodium starch glycollate remain unchanged for up to 3 - 5 years if it is
stored at moderate temperatures and humidity.
Incompatibilities:
Sodium starch glycollate is incompatible with ascorbic acid.
Method of manufacture:
Sodium starch glycollate is a substituted derivative of potato starch. Typically,
commercial products are also cross-linked. Starch is carboxymethylated by reacting it with
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sodium chloroacetate in an alkaline medium followed by neutralization with citric acid or
some other acid. Cross linking may be achieved either by physical methods or chemically
by using reagents such as phosphorusoxytrichloride or sodium trimetaphosphate.
Safety:
Sodium starch glycollate is widely used in oral pharmaceutical formulations and is
generally regarded as a nontoxic and nonirritant material. However, oral ingestion of large
quantities may be harmful.
Handling precautions:
Observe normal precautions appropriate to the circumstances and quantity of
material handled. Sodium starch glycollate may be irritant to the eyes; eye protection and
gloves are recommended. A dust mask or respirator is recommended for processes that
generate a large quantity of dust.
Regulatory acceptance:
Included in the FDA Inactive Ingredients Guide (oral capsules and tablets).Included
in non-parentral medicines licensed in the UK. Included in the Canadian List of Acceptable
Non-medicinal Ingredients.
Comments:
The physical properties of Sodium starch glycollate, and hence its effectiveness as a
disintegrate, are affected by the degree of cross linkage, extent of carboxymethylation, and
purity.
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II. CROSCARMELLOSE SODIUM [AC-DI-SOL] (Raymond C. Rowe et al., 2003)
Nonproprietary name:
USP NF Croscarmellose sodium
Synonyms:
AC-Di-sol; Cross-linked carboxymethyl cellulose sodium,Modified cellulose gum,
Nymcel 25x;Primellose, Solutab.Chemical name Cellulose, Carboxymethyl ether, sodium
salt, cross linked.
Molecular weight:
Typical molecular weight: 90,000 - 700000
Structural formula:
Functional category:
Tablet and Capsule disintegrate
Description:
Croscarmellose sodium occur odorless, white colored powders
LORATADINE MDT – AS NOVEL APPROACH DRUG AND EXCIPIENTS PROFILE
ADHIPARASAKTHI COLLEGE OF PHARMACY ,MELMARUVATHUR Page 69
Typical properties
Particle size distribution:
Not more than 2% retained on#200 (73.7m m)mesh and not more than 10% retained
on a #325 (44.5mm) mesh for Ac-Di-sol.
Solubility:
Insoluble in water although Croscarmellose sodium rapidly swells to 4-8 times its
original volume on contact with water
Stability and storage conditions:
Croscarmellose sodium is a stable though hygroscopic material. Amodel tablet
formulation prepared by direct compression with Croscarmellose sodium as disintegrate,
showed no significant difference in drug dissolution after storage at 30oC for 14 months.
Croscarmellose sodium should be stored in well-closed container in a cool, dry place.
Incompatibilities:
The efficacy of disintegrates, such as croscarmellose sodium maybe slightly reduced
in tablet formulations prepared by either wet direct compression or direct compression
process, which contain hygroscopic excipients as sorbitol.
Application in pharmaceutical formulation or technology:
Croscarmellose sodium is used in oral Pharmaceutical formulation as a disintegrate
for capsules, tablets and granules. In tablet formulation croscarmellose sodium may be used
in both direct compression and wet direct compression processes., when used in wet direct
compression the croscarmellose sodium is best added in both the wet and dry stages of the
process intra and extra granularly so that wicking and swelling ability of disintegrate is best
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utilized, concentrations of up to 5% w/w of croscarmellose sodium may be used as tablet
disintegrate although normally 2% is used in direct compression.
III. CROSPOVIDONE (Raymond C. Rowe, 2003)
Nonproprietary names:
BP Crosspovidone; PhEur Crospovidonum; USPNF Crospovidone.
Synonyms:
Crosslinked povidone, E1202 Kollidon CL,\XL-10, polyvinyl polypyrrolidone
PVP,1-vinyl 2 pyrrolidone homopolymer
Chemical name:
1- Etheny1-2 pyrrolidinone homopolymer
Empirical formula:
[C6H9NO]n
Structural formula:
Molecular weight;
> 1000000
Functional category:
Tablet disintegrate
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Description:
Crospovidone is white to creamy white, finely divided free flowing. Practically
tasteless, odorless or nearly odorless, hygroscopic powder.
Solubility:
Practically insoluble in water and most common organic solvents
Typical properties
Acidity / Alkalinity pH:
5.0-8.0(1%w/v aqueous slurry)
Density:
1.22 g/cm3
Bulk density:
Polyplasdone XL10 – 0.416 g/cm3
Moisture content:
Maximum moisture sorption is approximately60%Polyplasdone XL-10- 5.0 %
maximum.
Compressibility (Carr index):
Polyplasdone XL -10-30%
Particle size distribution:
Less than 74 μm for Polyplasdone XL-10
Specific surface Area:
Polyplasdone XL-10 1.2-1.4m2/g
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Stability and storage condition:
Since Crosspovidone is hygroscopic, it should be stored in an airtight container in
cool and dry place.
Application in pharmaceutical formulation or technology:
Crospovidone is a water-insoluble tablet disintegrates and dissolution agent used at
2-5% concentration in tablets prepared by direct compression or wet and dry Direct
Compression, It rapidly exhibits high capillary activity and Pronounced hydration capacity
with little tendency to form gels. The particle size of crospovidone strongly influences
disintegrate of tablets. Larger particle provide a faster disintegrate than smaller particles.
Crospovidone can also be used as solubility enhancer.
Incompatibilities:
Crospovidone is compatible with most organic and inorganic pharmaceutical
ingredients. When exposed to a high water level, Crospovidone may form molecular adduct
with some materials.
IV. AEROSIL (Raymond C. Rowe, 2003)
Nonproprietary names:
BP Colloidal anhydrous silica; PhEur Silica colloidal is an hydrica; USPNF
Colloidal silicon dioxide.
Synonyms:
Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica; light anhydrous
silicic acid; silicic anhydride; silicon dioxide fumed; Wacker HDK.
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Chemical name and cas registry number:
Silica [7631-86-9]
Empirical formula:
SiO2
molecular weight:
60.08
Functional category:
Adsorbent; anti caking agent; emulsion stabilizer; glidant; suspending agent; tablet
disintegrate; thermal stabilizer; viscosity-increasing agent
Applications in pharmaceutical formulation or technology:
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food
products; its small particle size and large specific surface area give it desirable flow
characteristics that are exploited to improve the flow properties of dry powders in a number
of processes such as tablet. Uses of colloidal silicon dioxide as follows;
Use in concentration (%)
Aerosols 0.5 to 2.0
Emulsion stabilizer 1.0 to 5.0
Glidant 0.1to 0.5
Suspending and thickening agent 2.0 - 10.0
Aerosil is also used to stabilize emulsions and as a thixotropic thickening and
suspending agent in gels and semisolid preparations with other ingredients of similar
refractive index, transparent gels may be formed. The degree of viscosity increase depends
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on the polarity of the liquid (polar liquids generally require a greater concentration of
colloidal silicon dioxide than non polar liquids). Viscosity is largely independent of
temperature. However, changes to the pH of a system may affect the viscosity.
Description:
Aerosil is submicroscopic fumed silica with a particle size of about15 nm. It is a
light, loose, bluish-white-colored, odorless, tasteless, nongritty amorphous powder.
Typical Properties
Acidity/alkalinity:
pH = 3.5 - 4.4 (4% w/v aqueous dispersion)
Density (bulk):
0.029 - 0.042 g/cm3
Density (tapped):
0.05 g/cm3
Flow ability:
35.52% (Carr compressibility index)
Solubility:
Practically insoluble in organic solvents, water, and acids, except hydrofluoric acid;
soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersion with water.
Specific surface area:
200 - 400 m2/g (Stroehlein apparatus, single point); 50 - 380 m2/g (BET method).
Several grades of colloidal silicon dioxide are commercially available, which are produced
by modifying the manufacturing process.
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Stability and storage conditions:
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water without
liquefying. Aerosil powder should be stored in a well-closed container. Some grades of
colloidal silicon dioxide have hydrophobic surface treatments that greatly minimize their
hygroscopity.
Incompatibilities:
Incompatible with diethylstilbestrol preparations
Method of manufacture:
Aerosil is prepared by the vapor hydrolysis of chlorosilanes, such as silicon
tetrachloride, at 1800°C using a hydrogen–oxygen flame.
Safety:
Colloidal silicon dioxide is widely used in oral and topical pharmaceutical products
and is generally regarded as an essentially nontoxic and nonirritant excipients. However,
intraperitoneal and subcutaneous injection may produce local tissue reactions
and/orgranulomas. Therefore it is not being administered parental.
LD50 (rat, IV) 15 mg/kg
LD50 (rat, oral) 3.16 g/kgs
Handling precautions:
Observe normal precautions appropriate to the circumstances and quantity of
material handled. Eye protection and gloves are recommended. Precautions should be taken
to avoid inhalation of colloidal silicon dioxide.
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VI. MANNITOL (Raymond C. Rowe, 2003)
Nonproprietary Names:
BP Mannitol; JP D-Mannitol; PhEur Mannitolum; USP Mannitol
Synonyms:
Cordycepic acid;C*PharmMannidex; E421; manna sugar; D-mannite; mannite;
Mannogem;Pearlitol.
Chemical name:
D-Mannitol
Empirical formula and molecular weight:
C6H14O6182.17
Structural formula:
Functional category:
Diluents; Diluents’ for Lyophilized preparations; Sweetening agent; Tablet and
Capsule diluents; Tonicity agent.
Applications in pharmaceutical formulation or technology:
Mannitol is widely used in pharmaceutical formulations and food products. In
pharmaceutical preparations it is primarily used as a diluents (10 - 90% w/w) in tablet
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formulations, where it is of particular value since it is not hygroscopic and may thus be used
with moisture-sensitive active ingredients .Mannitol may be used in direct-compression
tablet applications, for which the granular and spray-dried forms are available, or in wet
granulations.
Description:
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is
isomeric with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or free-
flowing granules. It has a sweet taste, approximately as sweet as glucose and half as sweet
as sucrose, and imparts a cooling sensation in the mouth. Mannitol shows polymorphism.
Typical properties
Density (bulk):
0.430 g/cm3 for powder; 0.7 g/cm3 for granules.
Density (tapped):
0.734 g/cm3 for powder; 0.8 g/cm3 for granules.
Density (true):
1.514 g/cm3
Dissociation constant:
pKa = 13.5 at 18°C
Flash point:
<150°C
Flow ability:
Powder is cohesive, granules are free flowing.
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Melting point:
166–168°C
Particle size distribution:
Pearlitol 300 DC maximum of 0.1% greater than 500 μˇm and minimum of 90%
greater than 200 μ+m in size;
Pearlitol 400 DC maximum of 20% greater than 500 μm and minimum of 85%
greater than 100 μm in size;
Average particle diameter is 250 μm for Pearlitol 300 DC, 360 μm for Pearlitol 400
DC and520 μm for Pearlitol 500 DC.
Solvent solubility at 20°C:
Soluble in Alkalis ,Ethanol (95%) 1 in 83, Practically in soluble in Ether and soluble
1 in 18 in Glycerin
Specific surface area:
0.37–0.39 m2/g
Storage conditions:
The bulk material should be stored in a well-closed container in a cool, dry place.
Method of manufacture:
Mannitol may be extracted from the dried sap of manna and other natural sources by
means of hot alcohol or other selective solvents. It is commercially produced by the
catalytic or electrolytic reduction of monosaccharide’s such as mannose and glucose.
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Handling precautions:
Observe normal precautions appropriate to the circumstances and quantity of
material handled. Mannitol may be irritant to the eyes; eye protection is recommended.
VII. MICROCRYSTALLINE CELLULOSE (Raymond C. Rowe, 2003)
Nonproprietary name:
BP Microcrystalline cellulose; PhEur Cellulose microcrystalline; USPNF
Microcrystalline cellulose.
Synonyms:
Avicel, cellulose gel, crystalline cellulose,E460, Emcocel, Fibrocel, Tabulose.
Chemical Name:
Cellulose
Empirical formula:
( C6H10O5)n, Where n~220.
Molecular Weight: 36000.
Structural Formula:
LORATADINE MDT – AS NOVEL APPROACH DRUG AND EXCIPIENTS PROFILE
ADHIPARASAKTHI COLLEGE OF PHARMACY ,MELMARUVATHUR Page 80
Functional category:
Adsorbent, Suspending agent, tablet and capsule diluents, tablet disintegrate.
Description:
Microcrystalline cellulose is purified; partially depolymerized cellulose that occurs
as a white colored, odorless, tasteless, crystalline powder composed of porous particles. It is
commercially available in different size particle grades which have different properties and
application.
Applications in pharmaceutical formulation or technology:
Microcrystalline cellulose is widely used in pharmaceutical is primarily as diluents
in oral tablet and capsule formulations. Where it is used in both wet Direct Compression and
direct compression processes. In addition to its use as a diluents. Microcrystalline cellulose
also has some lubricant and disintegrant properties that make it useful in tablet.
Typical Properties
Bulk density:
(MCC pH102) = 0.307 g/cm3
Tapped density:
(MCC pH102) = 0.307 g/cm3
Density:
(MCC pH102) = 1.554 g/cm3
Melting point:
260-2700C
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Particle size:
(MCC pH102) = 100mm
Particle size distribution:
Typical mean particle size is 20 to 200mm Different grades have different nominal
mean particle size (pH102) 100mm
Moisture content:
Less than 5% w/w However different grade may contain varying amount of water
Microcrystalline cellulose is hygroscopic (pH102) = 3.315%.
Solubility:
Slightly soluble in 5%w/v Sodium hydroxide solution, practically insoluble in water
dilutes acids and most organic solvent.
Incompatibilities:
Incompatible and strong oxidizing agents.
Stability and storage conditions:
Microcrystalline cellulose is a stable, though hygroscopic material the bulk material
should be stored in well closed container in a cool and dry place.
VIII. ASPARTAME (Raymond C. Rowe, 2003)
Nonproprietary names:
BP Aspartame;  PhEur Aspartamum;  USPNF Aspartame
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Synonyms:
3-Amino-N-(aì-carboxyphenethyl) succinamic acid N-methyl ester; 3-amino-N-
(aìmethoxycarbonylphenethyl) succinamic acid; APM; aspartyl phenylamine methyl
ester;Canderel; E951; Equal; methyl N-a_-L-aspartyl-L-phenylalaninate; NutraSweet; Pal
Sweet; Pal Sweet Diet; Sanecta; SC-18862; Tri-Sweet.
Chemical Name:
N-aò-L-Aspartyl-L-phenylalanine 1-methyl ester.
Empirical Formula
C14H18N2O5
Molecular Weight:
294.31
Structural Formula:
Functional Category:
Sweetening agent.
Applications in Pharmaceutical Formulation or Technology:
Aspartame is used as an intense sweetening agent in beverage products, food
products, and table-top sweeteners, and in pharmaceutical preparations including tablets,1,2
powder mixes, and vitamin preparations. It enhances flavor systems and can be used to
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mask some unpleasant taste characteristics; the approximate sweetening power is 180–200
times that of sucrose. Unlike some other intense sweeteners, aspartame is metabolized in the
body and consequently has some nutritive value 1 g provides approximately 17 kJ (4 kcal).
However, in practice, the small quantity of aspartame consumed provides a minimal
nutritive effect. Therapeutically, aspartame has also been used in the treatment of sickle cell
anemia.
Description:
Aspartame occurs as an off white, almost odorless crystalline powder with an
intensely sweet taste.
Typical Properties
Acidity/alkalinity:
pH = 4.5–6.0 (0.8% w/v aqueous solution).
Bonding index:
0.8 × 102 (worst case); 2.3 × 102 (best case).
Flow ability:
44% (Carr compressibility index)
Density (bulk):
0.5–0.7 g/cm3 for granular grade;0.2–0.4 g/cm3 for powder grade.
Density (tapped):
0.29 g/cm3 (Spectrum Quality Products)4
Density (true):
1.347 g/cm3
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Effective angle of internal friction:
43.0°
Melting point:
246–247°C
Solubility:
Slightly soluble in Ethanol (95%); sparingly soluble in Water. At 20°C the solubility
is 1%w/v at the iso-electric point (pH 5.2). Solubility increases at higher temperature and at
more acidic pH, e.g., at pH 2 and 20°C solubility is 10% w/v.
Stability and Storage Conditions:
Aspartame is stable in dry conditions. In the presence of moisture, hydrolysis occurs
to form the degradation products L-aspartyl-L-phenylalanineand 3-benzyl-6-carboxymethyl-
2,5-diketopiperazine. A third-degradation product is also known, ßæ-L-aspartyl-L-
phenylalaninemethyl ester. For the stability profile at 25°C in aqueous buffers, Stability in
aqueous solutions has been enhanced by the addition of cyclodextrins, and by the addition
of polyethylene glycol 400 at pH 2.7 However, at pH 3.5 - 4.5 stability is not enhanced by
the replacement of water with organic solvents. Aspartame degradation also occurs during
prolonged heat treatment; losses of aspartame maybe minimized by using processes that
employ high temperatures for a short time followed by rapid cooling. The bulk material
should be stored in a well-closed container, in a cool, dry place.
Incompatibilities:
Differential scanning colorimetry experiments with some directly compressible
tablet excipients suggests that aspartame is incompatible with dibasic calcium phosphate
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and also with the lubricant magnesium stearate. Reactions between aspartame and sugar
alcohols are also known.
Method of Manufacture:
Aspartame is produced by coupling together L-phenylalanine (or L-phenylalanine
methylester) and L-aspartic acid, either chemically or enzymatically. The former procedure
yields both the sweet α-aspartame and non sweet β-aspartame from which the α-aspartame
has to be separated and purified. The enzymatic process yields only α°-aspartame.
Safety:
Aspartame is widely used in oral pharmaceutical formulations, beverages, and food
products as an intense sweetener and is generally regarded as a nontoxic material. However,
the use of Aspartame has been of some concern owing to the formation of the potentially
toxic metabolites methanol, aspartic acid, and phenylalanine. Of these materials, only
phenylalanine is produced in sufficient quantities, at normal aspartame intake levels, to
cause concern. In the normal healthy individual any phenylalanine produced is harmless,
however it is recommended that aspartame be avoided or its intake restricted by those
persons with phenylketonuria. The WHO has set an acceptable daily intake for aspartame at
up to 40 mg/kg body-weight. Additionally, the acceptable daily intake of diketopiperazine
(an impurity found in Aspartame) has been set by the WHO at up to 7.5 mg/kg body-weight.
A number of adverse effects have been reported following the consumption of aspartame,
particularly in individuals who drink large quantities (up to 8 liters per day in one case) of
Aspartame-sweetened beverages. Reported adverse effects include headaches. Grand mal
seizure; memory loss; gastrointestinal symptoms; and dermatological symptoms. Although
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aspartame has been reported to cause hyperactivity and behavioral problems in children, a
double-blind controlled trial of 48 preschool-age children fed diets containing a daily intake
of 38 ± 13 mg/kg body-weight of aspartame for 3 weeks showed no adverse effects
attributable to aspartame, or dietary sucrose, on children’s behavior or cognitive function.
Handling precautions:
Observe normal precautions appropriate to the circumstances and quantity of
material handled. Measures should be taken to minimize the potential for dust explosion.
Eye protection is recommended.
Regulatory status:
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA
Inactive Ingredients Guide (oral powder for reconstitution, buccal patch, granules, film-
coated, and tablets).Included in non parental medicines licensed in the UK .Included in the
Canadian List of Acceptable Non-medicinal Ingredients.
Related substances:
Alitame.
5.2.6. MAGNESIUM STEARATE (Raymond C.R., et al., 2003)
Nonproprietary names:
BP :Magnesium stearate
JP :Magnesium stearate
PhEur :Magnesii stearas
USPNF :Magnesium stearate
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Synonyms:
Magnesium octa decanoate, Magnesium salt.
Chemical name and CAS registry number:
Octa decanoic acid magnesium salt [557-04-0]
Functional category : Tablet and capsule lubricant
Empirical formula : C36H70MgO4
Molecular weight : 591.3
Structural formula:
Mg2+
O
O
O
O-
Description:
It is a fine, white, precipitated or milled, impalpable powder of low bulk density and
having a faint odor of stearic acid, characteristic taste.
Solubility:
It is insoluble in water, ethanol and ether. It can slightly soluble in warm ethanol and
benzene.
Stability and storage conditions:
Stable, Store in a well closed container in a cool, dry place.
Materials
and
Equipment
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Table 6.1: List of materials and their suppliers
S. No. Materials Source
1 Loratadine Sun  pharma, Mumbai
2 Sodium starch glycollate Sun  pharma, Mumbai
3 Crospovidone Sun  pharma, Mumbai
4 Croscarmellose sodium(Ac-di-sol) Sun  pharma, Mumbai.
5 Aerosil LOBA chemie P.Ltd. Mumbai.
6 Magnesium stearate MADRAS pharmaceuticals, Chennai
7 Mannitol MADRAS pharmaceuticals, Chennai
8 Microcrystalline cellulose MADRAS pharmaceuticals, Chennai
9 Aspartame Orchid pharmaceuticals, Chennai.
10 Strawberry (flavor) Orchid pharmaceuticals,Chennai
6. MATERIALS AND METHODS
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Table 6.2: List of equipments with model/make
Sl.
No. Name of the Instruments Make Model
1 Electronic Balance Shimadzu, Japan BL- 200H.
2 UV-Visible Spectrophotometer Shimadzu, Japan 1700
3 16 station rotary tabletcompression machine
Cadmach, Ahmedabad,
India JMD-4-8
4 Hardness Tester Monsanto ---
5 Roche Friability Tester Veego scientifics,  Mumbai VET-DV
6 FTIR Spectrophotometer Perkin elmer-Pharmaspec-1 ----
7 USP, Type II Dissolution TestApparatus Veego scientifics,  Mumbai
VDA –
8DR.
8 USP, Disintegrate test apparatus Veego scientifics,  Mumbai VTD-DV
9 Digital pH Meter Elico scientifics,  Mumbai L1610
10 Hot air oven Prescision scientific co.,Chennai P-1401
11 Vernier Calipers Indolabs, Chennai ---
12 Humidity Chamber Labtech, Ambala ----
13 Tap Density Apparatus Indolabs, Chennai VTAP-M-2
14 Melting Point Test Apparatus Prescision scientific co.,Chennai ---
15 Standard sieve Jayant scientific, India ---
Experimental
work
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7.EXPERIMENTAL WORK
7.1 Preformulation study
7.1.1 Identification of drug
7.1.1.1 By FTIR spectroscopy
(Moffat A.C., 2004;Indian Pharmacopoeia, 2007;www.pharmpedia.com)
The infrared spectrum of Loratadine and polymers were recorded by using  FT-IR
(Schimadzu 8400 SCCE). A small quantity of sample was mixed with equal quantity of
potassium bromide and placed in sample cell to record its IR spectra.
7.1.1.2. By Melting point
Melting point is the one of important parameter for identification of pure drug and
it is tested by using melting point apparatus.
7.1.2. Physiochemical parameter
7.1.2.1. Organoleptic properties (Indian Pharmacopoeia, 2007)
The general appearance of a tablet, its visual identity and over all "elegance" is
essential for consumer acceptance. Included in are tablet’s sizes, shape, color, presence or
absence of an odour, taste, surface texture, physical flaws and consistency and legibility of
any identifying marking which was observed visually.
7.1.2.2. Solubility profile
Solubility is a useful parameter mainly for poorly soluble drugs. Bioavailability
problems are often present, when the solubility of a drug is less than 10 mg/ml over the
pH range 1-8. The solubility of drug was recorded by using various descriptive
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terminology specified in Indian pharmacopoeia, 2007. In this maximum amount of solvent
required to dissolve the solute was determined.
7.1.2.3. Loss on drying (Indian Pharmacopoeia, 2007)
Loss on drying is the loss of weight expressed as percentage w/w resulting from
water and volatile matter of any kind that can be driven off under specified condition. The
accurately weighed 1gm of sample was transferred in glass-stoppered, hallow weighing
bottle and accurately weighed the bottle. The bottle was transferred in oven and substance
was dried at 105°C for 3 hours. The bottle was removed from oven and reweighed; loss on
drying was calculated by following equation,
Initial weight of substance – Final weight of substance
Loss on drying = × 100
Initial weight of substance
7.1.3. Analytical methods
7.1.3.1. Determination of absorption maximum in Solvents
10 mg of Loratadine was weighed and transfer in to 3 individual  100 ml standard
flask and made up to the mark with methanol, 0.1N HCL and Phosphate Buffer pH 6.4
separately. From the above solution took each 1 ml from each solution and make up with
10 ml standard flask to get the concentration of 10 µg/ ml of each solution. Each blank
was kept separately and scan in the region 200 - 400 nm and determine the absorption
maxima of drug in three solvents. 247.5 nm for 0.1N  HCl, 275.0 nm for Methanol, 274.0
nm for Phosphate buffer 6.8.
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7.1.3.2. Preparation of standard calibration curve of loratadine in solvents
A stock solution of Loratadine from the above solution and to get the
concentration of 5 to 30 µg/ ml in three solvents and its obey the beer’s law.
7.1.3.3. Determination of percentage purity of drug (IP 2007)
Accurately weighed 100 mg of loratadine was dissolved in little quantity of 0.1 N
HCl and volume was adjusted to 100 ml with the same to prepare standard solution having
concentration of 1000 µg/ ml. From the above solution, aliquots of 3 ml were transferred
to 10 ml volumetric flasks and final volume was made to 10 ml with 0.1N HCl.
Absorbance values of these solutions were measured against blank (0.1N HCl) at 275 nm
using Shimadzu-1700 Pharmaspec UV-Visible spectrophotometer. The percentage purity
of drug was calculated by using calibration graph method (least square method).
7.1.4. Determination of drug-polymer compatibility
7.1.4.1. By Fourier Transforms Infra-Red (FTIR) Spectroscopy
(Moffat A.C, 2004;Roberat M. Silverstein, 2003; Sajal kumar Jha, Divakar goli.2008)
Infrared spectra matching approach was used for the detection of any possible
chemical reaction between the drug and the superdisintegrants. A physical mixture (1:1)
of drug and superdisintegrants was prepared and mixed with suitable quantity of
Potassium bromide. About 100mg of this mixture was compressed to form a transparent
pellet using a hydraulic press at 10 tons pressure. It was scanned from 4000 to 400 cm-1 in
a Parkin elmer-Pharmaspec-1 FTIR Spectrophotometer. The IR spectrum of the physical
mixture was compared with those of pure drug and matching was done to detect any
appearance or disappearance of peaks.
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Parameters of I. R. Spectrum
Measuring Mode      : % T (0-100%T)
Resolution                :  4.0 cm-1
Detector                    :Detector 1(2.8 mm/sec)
Apodization              : HAPP – GENZEL
Gain                          :Auto
Wavelength              : 4000 – 400 cm-1
The drug superdisintegrants interaction was carried out using FT-IR (Parkin elmer-
Pharmaspec-1). Individual IR spectra of drug and superdisintegrant as well as in
combination were taken and compared to see if interaction has occurred or not. The above
stated procedure is followed to record IR spectra.
7.1.4.2. By Differential Scanning Calorimetry Study (DSC) (Chatwal G. R., 2007)
In drug formulation it is essential to evaluate the possible interactions between the
active principle and the superdisintegrants, as the choice of the superdisintegrants should
be performed in relation to the drug delivery, to their compatibility with the same drug
and to the stability of the final product. Loratadine powder was mixed with various
superdisintegrants in the ratio of 1:1 and the resulting physical mixture was kept in sealed
glass vials. Mixture should be examined under Nitrogen to eliminate oxidative and
pyrolytic effect at a standard heating rate (2, 5 or 100C/minute) on DSC. Thermograms of
pure drug are used as a reference.
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Appearance or disappearances of one or more peaks in thermogram of drug with
polymer are considered as an indication of interaction.
7.1.5. Formulation and characterization of powder blend
(Lachman L, 1991;Bankar G.S..1996)
Method
Accurate quantity of drug and all ingredients were weighed according to formula
shown in Table 7.1 and powder except aerosil and magnesium sterate was blended
homogeneously in mortor and pestel for 15 minutes. Prepared powder blend was passed
through sieve No.#60. Finally aerosil and magnesium sterate  passed through sieve
No. #30 was added and further mixed for10 minutes. The powder blend was evaluated for
angle of repose, bulk density, Tapped density, Compressibility Index and Hausner ratio.
7.1.5.1.
7.1.5.2. Angle of Repose
Angle of repose was determined using cylinder method. The blend was poured
through a funnel that can be raised vertically until a maximum cone height (h) was
obtained. Radius of the heap (r) was measured and the angle of repose (q) was calculated
using the formula
Ɵ = tan¯¹(r/ h)
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Method
Weighted quantity of Loratadine was passed through funnel kept at height at 9 cm
from base. The powder forms heap and touches the tip of the funnel. The radius was
measured and angle of repose was calculated.
Table 7.1: Standard Relationship between Angle of Repose (Ө) and Flow ability
Angle of repose (Ө) Flowability
< 20 Excellent
20-30 Good
30-34 Passable*
> 40 Very poor
*Adding glidant for improving flow
7.1.5.2. Bulk density
Apparent bulk density (ρb) was determined by pouring blend into a graduated
cylinder. The bulk volume (Vb) and weight of the powder (M) was determined.The bulk
density was calculated using the formula.
ρ b =M/Vb (or)
BD = Weight of the powder/Volume of the powder.
7.1.5.3. Tapped density
It was determined by placing a graduated cylinder, containing a known mass of
drug excipients blend, which was tapped for a fixed time until the powder bed volume has
reached a minimum. The minimum volume (Vt) occupied in the cylinder and the weight
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(m) of the blend was measured. The tapped density (ρt) was calculated using the following
formula.
ρt = m /Vt (or)
TBD = Weight of the powder/Tapped volume of the powder
7.1.5.4. Compressibility Index
The simplest way for measurement of free flow of powder is compressibility, a
indication of the case with which a material can be induced to how is given by
compressibility index (I) which is calculated as follows
Carr’s compressibility index (%) = [(TBD-BD)/ TBD x100
Table 7.2: Table shows standard values of Carr’s index
Carr’s index Flowability
5-15 Excellent
12-16 Good
18-21 Fair Passable
23-35 Poor
33-38 Very poor
> 40 Very very poor
The value below 15% indicates a powder with usually give rise to good flow
characteristics, whereas above 25% indicate poor Flow ability.
7.1.5.5. Hausner’s ratio
Hausner’s ratio is an indirect index of ease of powder flow. It is calculated by the
following formula;
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Hausner’s ratio= ρt/ρb
Where, ρt is tapped density and ρb is bulk density
A hausner’s ratio less than 1.25 indicates good flow while greater than 1.5 indicates poor
flow.
7.2. Formulation of Mouth Dissolving Tablet of Loratadine
Table 7.3: Formulated Composition of different Batches of Mouth Dissolving
Loratadine Tablets
S.
No.
Ingredients
(mg/tab)
Formulation code
F1 F2 F3 F4 F5 F6 F7 F8 F9
1 Loratadine 10 10 10 10 10 10 10 10 10
2 Croscarmellose
sodium (Ac-di-sol) 4 6 8 - - - - - -
3 Sodium starch
glycollate(Explotab) - - - 4 6 8 - - -
4 Crospovidone
(Polyplasdone) - - - - - - 4 6 8
5 Microcrystalline
cellulose 74 72 70 74 72 70 74 72 70
6 Mannitol 100 100 100 100 100 100 100 100 100
7 Aerosil 4 4 4 4 4 4 4 4 4
8 Aspartame 6 6 6 6 6 6 6 6 6
9 Magnesium stearate 2 2 2 2 2 2 2 2 2
10 Strawberry flavour q.s q.s q.s q.s q.s q.s q.s q.s q.s
11 Total 200 200 200 200 200 200 200 200 200
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7.2.1. Preparation of mouth dissolving loratadine tablets
Method
The mouth dissolving tablets were prepared by direct compression method with
the use of three different superdisintegrants namely Croscarmellose sodium, Sodium
starch glycolate , Crospovidone in the ratio of 5:2, 5:3 and 5:4. Microcrystalline cellulose,
Mannitol was used as a diluents as and mixture of Aerosil and Magnesium sterate (2:1)
was used as a glidant and lubricant respectively. The composition of mouth dissolving
formulation was shown in Table 7.3.
Accurate quantity of drug and all ingredients were weighed according to formula shown in
Table 7.3 and powder except Aerosil and Magnesium sterate was blended homogeneously
in mortor and pestle for 15 minutes. Prepared powder blend was passed through sieve no.
#60. Finally Aerosil and Magnesium sterate passed from sieve no. #30 added and was
further mixed for10 minutes.
Accurately weighed 200 mg homogeneously mixed powder blend was fed
manually and compressed with constant compression force and hardness on 16 stations
Cadmach tablet compression machine with 9 mm, breakthrough, and flat faced punches.
Total nine formulations were prepared.
7.3. Evaluation of Loratidine MDTs
7.3.1. Appearance
The tablets were visually observed for capping, chipping and lamination.
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7.3.2 Weight Variation
Method
Twenty tablets were randomly selected from each batch and individually weighed.
The average weight and standard deviation of 20 tablets was calculated. The batch passes
the test for weight variation test if not more than two of the individual tablet weight
deviate from the average weight.
Table 7.4: Specifications of % weight variation allowed in tablets as per indian
pharmacopoeia
Average Weight of Tablet %  Deviation Allowed
80 mg or less 10
More than 80 mg
but less that 250 mg 7.5
250 mg or more 5
7.3.3 Thickness uniformity
Method
Three tablets were selected randomly from each batch and thickness was measured
by using Vernier Caliper.
7.3.4 Hardness (Lachman L,1991; Bankar G.S.,1996)
Hardness or tablet crushing strength (Fo) the force required to break a tablet in a
diametric compression was measured using Monsanto Hardness Tester.
For each formulation, the hardness of 6 tablets was determined using the Monsanto
hardness tester. The tablet was held along its oblong axis in between the two jaws of the
LORATADINE MDT – AS NOVEL APPROACH EXPERIMENTAL WORK
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 100
tester. At this point, reading should be zero kg/cm2. Then constant force was applied by
rotating the knob until the tablet fractured. The value at this point was noted in kg/cm2 .
7.3.5 Friability (Lachman L,1991; Bankar G.S.,1996)
Friability of the tablets was determined using Roche Friabilator. This device
subjects the tablets to the combined effect of abrasions and shock in a plastic chamber
revolving at 25 rpm and roping the tablets ata height of 6 inches in each revolution.
Preweighed sample of tablets was placed in the Friabilator and were subjected to 100
revolutions. Tablets were dedusted using a soft muslin cloth and reweighed, the friability
(F) is given by the formula.
% F = (Initial wt. - Final wt. / Initial wt.) x 100.
7.3.6.Content uniformity (Indian pharmacopoeia,2007;www.pharmpedia.com)
The Loratadine content in the tablets was estimated as follows.
Method
20 tablets were finely powdered and weight equivalent to 10 mg of Loratadine was
dissolved in 100 ml of methanol and assayed for drug content using UV-Visible
spectrophotometer at 275.00 nm.
7.3.7 Disintegration time (Indian Pharmacopoeia, 2007;Chaudhari P.D., 2005)
Method
The Disintegration time of the tablets was determined as per Indian
Pharmacopoeia monograph. The test was carried out using USP disintegrate test
apparatus, (Veego scientific VTD-DV). It consists of an apparatus in which 6 tablets was
introduced into each of six cylindrical tubes, the lower end of which was covered by a
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0.025 in wire mesh. The tubes were then raised and lowered through a distance of 5.3 to
5.7 cm in a test fluid phosphate buffer pH 6.8 and 0.1N HCl pH 1.2 as a disintegrating
media maintained at 370 ± 20 C. and the time in second taken for complete disintegrate of
the tablet with no palpable mass remaining in the apparatus was measured in seconds.
7.3.8 Wetting time of water absorption Ratio
(Chaudhari P.D., 2005; Gattani S. G.,2009)
The wetting time characteristic of the loose disintegrant powder allows an
evaluation of both the intrinsic swelling and the wettability of the superdisintegrants.
Wetting time of the ODT is important parameter, which needs to be assessed to give an in
sight into the disintegrate properties of the tablets; a lower wetting time implies a quicker
disintegrate of the tablet. Wetting time was performed at room temperature.
A piece of tissue paper of 10cm folded twice was placed in small petri dish of
diameter 10cm containing 6 ml of water. A tablet was put on the paper and the
timerequired for water to reach upper surface of tablet was noted.
For water absorption ratio the same wetted tablet was taken out from petri dish and
weighed.Water absorption ratio (R) was determined by using following equation.
R=100×Wa- Wb/Wb
Where,
Wb =Weight of tablet before water absorption
Wa = Weight of tablet after water absorption
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7.3.9 In-vitro Dissolution studies
(Indian Pharmacopoeia, 2007; Gattani S. G.,2009; Kuchekar B.S.,2004)
Method
Dissolution profiles of  Loratadine tablets were determined using the USP Type II
Dissolution test apparatus (Veego scientific VDA-8DR) set with a paddle speed of 100
rpm. Dissolution was performed in 900 ml of 0.1N HCl maintained at 370± 0.50C. Aliquot
of  dissolution medium, 5 ml was with drawn at 3, 6, 9, up to 12 min with 5minutes
interval, and filtered through Whatmann filter paper. The amount of drug dissolved was
determined by UV-Visible spectrophotometer (Shimadzu-1700 Pharmaspec UV-VIS
Spectrophotometer) by measuring  the absorbance of the sample at 247.5 nm. An equal
volume of fresh medium, prewarmed at 37oC was replaced into the dissolution medium
after each sampling to maintain the constant volume throughout the test. Three trials for
each batch were performed and average percentage drug release was calculated by using
PCP disso V3 software.
7.4.  Stability studies of the tablets (www.ich.org.com,Chaudhari P.D.,2005)
Stability of a formulation can be defined as the time from date on manufacture of
the formulation until its chemical or biological activity is not less than a predetermined
level of labeled potency and its physical characteristics have not changed appreciably or
deleteriously. Formulation and the development of a pharmaceutical product are not
complete without proper stability analysis, carried out on it to assess the physical and
chemical stability and the safety. The purpose of stability testing is to provide evidence on
how the quality of a drug substance or drug product varies with time. Under the influence
LORATADINE MDT – AS NOVEL APPROACH EXPERIMENTAL WORK
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 103
of a variety of environmental factors such as temperature, humidity and light, enabling
recommended storage conditions, re-test periods and shelf lives.
Generally, the observation of the rate at which the product degrades under normal
room temperature requires a long time. To avoid the undesirable delay, the principles of
accelerated stability studies are adopted.
The International Conference on Harmonization (ICH) Guidelines titled “Stability
testing of new drug substance and products” (QIA) describes the stability test
requirements for drug registration application in the European Union, Japan and United
States of America.
ICH specifies the length of study and storage conditions.
Long-term testing 25oC ± 2oC/60 % RH ± 5% for 12 months.
Short term testing 30oC ± 2oC/65 % RH ± 5% for 1 month.
Accelerated testing 40oC ± 2oC/75 % RH ± 5% for 6 months.
Stability studies for the present work carried out at 40oC ± 2oC/75% ± 5% RH for
the selected formulation for 3 months.
Method
The selected formulations were packed in tightly closed container which were
tightly plugged with cotton and capped. They were then stored at 40oC ± 2oC /75 % RH
± 5% for 3 months and evaluated for their physical appearance, hardness, disintegrate
time, dissolution testing and drug content at specified intervals of time. The drug solutions
were further scanned to observe any possible spectral changes.
Results
and
Discussion
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8. RESULTS AND DISCUSSION
In the present study, an attempt was made to formulate nine formulations of the
mouth dissolving tablets of Loratadine were prepared with different level addition of
superdisintegrants; sodium starch glycollate, crosspovidone and Croscarmellose sodium,
For each designed formulations, powder mixed blend of drug and excipients was prepared
and evaluated for various parameters as follows.
8.1. Preformulation parameters
8.1.1. Identification of drug
8.1.1.1. By FTIR spectroscopy
Figure 8.1: FTIR spectra for Loratadine
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Table 8.1: Characteristic frequencies (Interpretation) in IR spectrum of Loratadine
Wave No.(cm-1) Inference
1702.28 C=O stretching
713.22 C-Cl stretching
3037.27 C-H stretching of pyridine
1591.37 C=N stretching of pyridine
2982.06 C-H stretching of aromatics
1579.60 C-C skeletal stretching
1355.68 C-N  stretching of tertiary amine
Major functional groups present in Loratadine show characteristic peaks in IR
spectrum. Table 8.1 shows peaks observed at different wave numbers and the functional
group associated with these peaks. The major peaks are identical to functional group of
Loratadine. Hence, the sample was confirmed as Loratadine.
8.1.1.2. By melting points
Melting range of Loratadine sample was found to be 135.00 ± 10C. The reported
melting point range for Loratadine is 134 to 136ºC. Hence, experimental values are in good
agreement with official values.
8.1.2. Physicochemical parameters of drug
8.1.2.1.Organoleptic properties
Colour:White
Nature: Fine powder
Odour:Odourless
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8.1.2.3. Solubility study of the drug
Table 8.2: The solubility of Loratadine in different solvents
S. No. Solvent
Parts of solvent required
per part of solute Inference
1 Distilled water 1000 Practicallly
Insoluble
2 Acetone 2 Freely Soluble
3 Methanol 2 Freely Soluble
4 Chloroform 2 Freely Soluble
5 Toluene 2 Freely Soluble
6 0.1 N HCl 2 Freely Soluble
8.1.4 Loss on drying
The percentage loss on drying after 4 hours was found to be 0.4%. The sample
passes test for loss on drying as per the limits specified in I.P.(N.M.T. 0.5%).
Table 8.3: Percentage loss on drying for Loratadine
S. No. Percentage  LOD Avg. percentage LOD
1 0.3
0.3±0.12 0.2
3 0.4
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8.1.5 Analytical Methods.
8.1.5.1. Determination of λmax. and Preparation of Calibration Curve of
Loratadine by using 0.1 N HCl.
UV absorption spectrum of Loratadine in 0.1 N HCl shows λmax at 247.5 nm.
Absorbance obtained for various concentrations of Loratadine in 0.1 N HCl are given in
table 8.4.The graph of absorbance vs. concentration for Loratadine was found to be linear in
the concentration range of 10μg /ml. The drug obeys Beer- Lambert’s law in the range of 10
μg /ml.
Figure 8.2: UV Spectra of Loratadine in 0.1 N HCl
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Table 8.4: Data of Concentration and Absorbance
S. No. Concentration (μg/ml) Absorbance at 247.5  nm
1 5 0.186
2 10 0.339
3 15 0.527
4 20 0.663
5 25 0.879
6 30 1.050
Figure 8.3: Calibration curve for Loratadine in 0.1 N HCl
The values of Correlation coefficient (R), Slope, Intercept obtained from the
calibration curve are given in the following table.
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Table 8.5: Data for Calibration Curve Parameters
S. No. Parameters Values
1 Slope (m) 0.03472
2 Intercept(c) 0.00014
3 Correlation coefficient (R) 0.99915
8.1.5.2 Determination of λ max and Preparation of Calibration Curve of   Loratadine
by using Methanol
UV absorption spectrum of Loratadine in Methanol shows λmax at 275 nm.
Absorbance obtained for various concentrations of Loratadine in Methanol are given in
table 8.6. The graph of absorbance vs. concentration for Loratadine was found to be linear
in the concentration range  of 10μg /ml. The drug obeys Beer Lambert’slaw in the range of
10 μg /ml.
Figure 8.4: UV spectra of Loratadine in Methanol
LORATADINE MDT – AS NOVEL APPROACH RESULT AND DISCUSSION
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 110
Table 8.6: Data of concentration and absorbance
S. No. Concentration (μg/ml) Absorbance at 275 nm
1 5 0.1623
2 10 0.3256
3 15 0.4894
4 20 0.6543
5 25 0.8143
6 30 0.9768
Figure 8.5: Calibration curve for Loratadine in Methanol
Table 8.7: Data for calibration curve parameters
S. No. Parameters Values
1 Slope (m) 0.032594
2 Intercept(c) 0.0000536
3 Correlation coefficient (R) 0.9999
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8.1.5.3. Determination of  λmax and preparation of calibration curve of
Loratadine by using phosphate buffer pH 6.8
UV absorption spectrum of Loratadine in phosphate buffer pH 6.8 shows λmax at
274 nm. Absorbance obtained for various concentrations of Loratadine in phosphate buffer
pH 6.8 are given in table 8.8. The graph of absorbance Vs concentration for Loratadine was
found to be linear in the concentration range of 10μg /ml. The drug  obeys Beer- Lambert’s
law in the range of 10 μg/ml.
Figure 8.6: UV spectra of Loratadine in Phosphate buffer pH 6.8
Table 8.8: Data of concentration and absorbance.
S. No. Concentration (μg/ml) Absorbance at 274 nm
1 5 0.2438
2 10 0.4891
3 15 0.7338
4 20 0.9945
5 25 1.2396
6 30 1.4921
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Figure 8.7: Calibration curve for Loratadine in Phosphate buffer pH 6.8
The values of Correlation coefficient (R), Slope, Intercept obtained from the
calibration curve are given in the following table.
Table 8.9: Data for calibration curve parameters
S. No. Parameters Values
1 Slope (m) 0.049809
2 Intercept(c) 0.0053
3 Correlation coefficient (R) 0.999963
8.1.2.3. Percentage purity of pure drug
The percentage purity of drug was calculated by using calibration graph method
(least square method).
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Table 8.10: Percentage purity of pure drug
All values are expressed as mean± SE, n=3.
The reported percentage purity for Loratadine is 99 to 101% (I.P. 2007).
8.1.6. Fourier Transform Infra-Red Spectroscopy (FT-IR)
Major functional groups present in Loratadine show characteristic peaks in IR
spectrum. Table No.8.11 shows peaks observed at different wave numbers and the
functional group associated with these peaks.The major peaks are identical to functional
group of Loratadine. Hence, the sample was confirmed as Loratadine.
Figure.8.8: FTIR spectrum of Loratadine
S. No. Percentage purity (%) Avg. percentage purity (%)
1 100.98
100.10 ± 0.642 99.64
3 99.58
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8.1.7. Drug and superdisintegrant compatibility studies
Figure 8.9: FTIR spectra for Loratadine + croscarmellose sodium
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Figure 8.10: FTIR spectra for Loratadine + crospovidone
Figure 8.11: FTIR spectra for Loratadine + sodium starch glycolate
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Table 8.11: Interpretation of FTIR Spectra of Loratadine
Wave No.
(cm-1) Functional group
Peak observed (Yes/No)
Drug Drug + CCS Drug +SSG Drug +  CP
1702.28 C=O stretching Yes Yes Yes Yes
713.22 C-CL stretching Yes Yes Yes Yes
3037.62 C-H stretching Yes Yes Yes Yes
1591.37 C-=N stretching Yes Yes Yes Yes
2982.06 C-H stretching Yes Yes Yes Yes
1579.60 C-C skeletalstretching Yes Yes Yes Yes
1355.68 C-N stretching oftertiary amine Yes Yes Yes Yes
SSG =Sodium starch glycollate, CP= Crospovidone, CCS = Croscarmellose sodium
Observation
Drug-excipient mixture does not produce any significant changes in organoleptic
property, bulk density, true density, compressibility index, angle of repose and drug content.
The compatibility between the drug and the selected superdisintegrants were evaluated
using FTIR peak matching method.
From above interpretation table it was concluded that, there was no appearance or
disappearance of the Principal peaks in the superdisintegrants drug mixture, which
confirmed the absence of any chemical incompatibility between the drug and the
superdisintegrants.
LORATADINE MDT – AS NOVEL APPROACH RESULT AND DISCUSSION
ADHIPARASAKTHI COLLEGE OF PHARMACY , MELMARUVATHUR Page 117
8.1.7.Differential scanning calorimetry:
The compatibility and interactions between drug and polymer were checked using
differential scanning calorimetry results obtained were shown in Figures: 8.12, 8.13, 8.14,
and 8.15. Table 8.11
Figure 8.12: DSC of Loratidine
Figure 8.13: DSC of Loratidine + Croscarmellose sodium
Figure 8.14: DSC of Loratidine + Sodium starch glycolate
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Figure 8.15: DSC of Loratidine + Crospovidone
According to Figures 8.12 to 8.15 and Table 8.12, DSC thermogram showed that
there was no major difference in onset temperature, end set temperature and peak
temperature when compared with pure drug thermogram. Therefore it could indicate that
there was no incompatibility between drug and different polymers.
Table 8.12: DSC thermogram parameters of Loratadine with various polymers
S. No. DSC thermogram
Onset
temperature
(°C)
Peak
temperature
(°C)
End set
temperature
(°C)
1 Loratadine 134.13 139.56 148.00
2 Loratadine + CCS 134.17 140.32 154.55
3 Loratadine+ SSG 135.66 141.26 149.67
4 Loratadine + CP 135.75 140.55 149.16
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8.2. Evaluation Of Powder Blends Of Loratadine
Table 8.13:Evaluation of Powder Blends of Loratadine
Formulation
Code
Bulk
density(g/ml)
Tapped
density(g/ml)
Angle of
repose(Ө)
Carr’s
index(%)
Hausner’s
ratio
F1 0.45±0.0125 0.50±0.0231 31.78±1.8815 11.19±0.00 0.8880±0.00
F2 0.43±0.0165 0.49±0.0099 30.67±0.9514 11.45±0.00 0.8854±0.00
F3 0.45±0.0042 0.50±0.0063 34.53±1.7870 9.56±0.00 0.9043±0.00
F4 0.41±0.0105 0.47±0.0124 28.42±1.2725 12.26±0.00 0.8773±0.00
F5 0.45±0.0090 0.52±0.0213 33.78±1.4577 13.79±0.00 0.8620±0.00
F6 0.47±0.0120 0.54±0.0217 29.04±1.1461 12.69±0.00 0.8730±0.00
F7 0.46±0.0103 0.50±0.0107 33.65±0.5445 9.65±0.00 0.9034±0.00
F8 0.48±0.0134 0.56±0.0216 28.66±1.673 14.18±0.00 0.8581±0.00
F9 0.43±0.0171 0.48±0.0263 26.59±0.4705 10.31±0.00 0.8968±0.00
All values are expressed as mean± SE, n=3.
8.2.1. Angle of Repose:
The Angle of repose of various powder mixed blends, prepared with different
superdisintegrants, was measured by funnel method.Angle of repose was found in the range
26.59 ± 0.4705 - 34.530 ± 1.7870. The good flow ability of powder blend was also
evidence with angle of repose.
8.2.3. Bulk density
The bulk density of various powder mixed blends prepared with different
superdisintegrants was measured by graduated cylinder. The bulk density was found in the
range 0.41 ± 0.0105 - 0.48 ± 0.0134 g/ml
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8.2.4. Tapped Density
The Tapped density of various powder mixed blends prepared with different
superdisintegrants was measured by using measuring cylinder.The tapped density was found
in the range 0.47 ± 0.0124 - 0.56 ± 0.0216 g/ml.These values indicate good packing
characteristics and the powder was not bulky.
8.2.5. Compressibility Index
The Compressibility index of various powder mixed blends, prepared with different
superdisintegrants, using bulk density and tappeddensity data, compressibility index was
calculated. It was found in the range 9.56 ± 0.00 - 14.18± 0.00 %. This indicates good flow
properties.
8.2.6. Hausner’s ratio
The Hausner’s ratio of various powder mixed blends, prepared with different
superdisintegrants, it is calculated by using bulk density and tapped density data. It was
found in the range of 0.8581 ± 0.00 – 0.9043 ± 0.00, reveals good flow properties(<1.25)
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8.3. Evaluation of Loratadine Tablets
Table 8.14: Evaluation of Loratadine tablets.
Formulation
Code
Dimension
Hardness
(kg/cm2)
Friability
(%)
Drug
content
(%w/w)
Weight
variation
Thickness
(mm)
Diameter
(mm)
F1 2.90±0.10 7.86±0.20 3.26± 0.05 0.8±0.05 98.50±0.11 204.6± 1.18
F2 2.9±0.17 7.73±0.32 3.36± 0.11 0.8±0.15 98.75±0.01 205.15 ± 1.59
F3 2.76±0.25 7.83±0.24 3.26± 0.15 0.9±0.1 98.25±0.15 206.15 ± 1.63
F4 2.80±0.10 7.96±0.20 3.36± 0.15 0.9±0.13 95.25±0.13 207.15 ± 1,53
F5 2.70±0.17 7.76±0.32 3.33± 0.25 0.8±0.07 98.50±0.06 207.10 ± 1.61
F6 3.0±0.10 7.80±0.45 3.4± 0.10 0.8±0.09 97.70±0.23 205.10 ± 1.48
F7 2.86±0.11 7.93±0.35 3.4± 0.10 0.8±0.06 97.75±0.14 206.40 ± 1.66
F8 2.96±0.05 7.76±0.30 3.4± 0.10 0.9±0.10 98.75±0.17 207.15 ± 1.53
F9 2.8±0.10 7.83±0.20 3.0± 0.10 0.9±0.11 98.75±0.01 201.55 ± 1.63
All values are expressed as mean± SE, n=3.
8.3.1. Dimension (Thickness and Diameter):
Tablets were evaluated by using Vernier caliper. Excessive variation in the tablet
thickness and diameter can result in problems with packaging as well as consumer
acceptance. There were no marked variations in the thickness and diameter of tablets within
each formulation indicating uniform die fill throughout the compression process.
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The size (diameter) of the tablets of all formulations was found to be
7.73 ± 0.3214 – 7.96 ± 0.2081 mm and thickness ofthe tablets was found in the range of
2.70 ± 0.17 mm – 3.0 ± 0.10 mm.
8.3.2. Weight variation
Tablets were prepared using direct compression technique. Since the material was
free flowing, tablets were obtained of uniform weight due to uniform die fill. Tablets were
obtained in the range with acceptable weight variations as per Pharmacopoeia
specifications, less than 7.5.
8.3.3.Hardness
Tablets were evaluated by using Monsanto Hardness tester. Hardness of the tablets
was in the range 3.0 ± 0.1 - 3.4 ± 0.1 kg/cm2. Uniform hardness was obtained due to equal
compression force. The obtained hardness range showed good mechanical strength with an
ability to withstand physical and mechanical stress conditions.
8.3.4. Friability
Tablets were evaluated by using Roche Friabilator and friability of tablets was
observed in acceptable range. 0.8 ± 0.090 - 0.9 ± 0.117 (less than 1%) This indicated a good
mechanical resistance of the prepared mouth dissolving tablets.
8.3.5. Drug content of Loratadine
Tablets were evaluated by using assay method. The drug content was obtained in the
acceptable limit. The drug content was found in therange 95.25 ± 0.13 - 98.75 ± 0.01
%w/w. (i.e. 99-101% w/w). The found range was within the specified limit as per Indian
Pharmacopoeia 2007.
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8.3.6. Disintegration time
Tablets were subjected for the in-vitro disintegrate time in the USP Disintegrate test
apparatus.(Veego scientific VTD-DV) The in-vitro disintegrate time for all nine
formulations varied from 12 ± 1.8973 to 30 ± 1.8973 seconds. The rapid disintegrate was
seen in the formulations containing Crospovidone and Croscarmellose sodium. This is due
to rapid intake of the water from the medium, swelling and burst effect. It also noticed that
the concentration of Croscarmellose sodium followed by Crospovidone and Sodium starch
glycollate increased, the time taken for the disintegrate was reduced.
Figure 8.16. Reveals that the formulations with highest concentration of Croscarmellose
sodium with Crospovidone shown significant rapid disintegrate.
Disintegrate time was to be found very less for F9 formulation which contains highest
concentration and efficiency of Crosspovidone
Figure 8.16: Disintegration of tablet
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Table 8.15:Disintegration time in seconds
All values are expressed as mean± SE, n=3.
Figure 8.17: Disintegrate profile of mouthdissolving Loratadine tablets (F1 - F9)
8.3.7. Wetting time and water absorption ratio
The wetting time for all nine formulations was performed in duplicate. The values
lie between 11 ± 1.4142 to 42 ± 1.8973 seconds. The wetting time was rapid in
Crosscarmellose sodium followed by Crosspovidone and Sodium starch glycollate. Here
Formulations Disintegrate time (sec)(Mean ± S.D. n = 3)
F1 25±3.2863
F2 19±1.4142
F3 15±1.4142
F4 30±1.8973
F5 22±1.4142
F6 18±1.4142
F7 20±2.000
F8 15±1.4142
F9 12±1.8973
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also it was observed that as the concentration of disintegrant increased the time taken for
wetting was reduced.
Water absorption ratio which is important criteria for understanding the capacity of
disintegrants to swell in presence of little amount of water was calculated. It was found in
the range of 78.45 ± 5.92  to 125.80 ± 5.10 %. (table 8.16) Water absorption ratio (R)
increases with the increased concentration of Croscarmellose sodium followed by
crosspovidone and sodium starch glycollate. Hence Crospovidone had shown highest
water absorption 125.80 % of F9 and in turn rapid bursting of the same formulations.
Table 8.16:Wetting time and Water absorption ratio
Formulation Wetting time(sec) Water absorption ratio
(%)
F1 25±3.2863 81.26±0.9832
F2 20±2.0000 90.28±3.982
F3 17±1.4142 117.40±1.88
F4 42±1.8973 78.45±5.92
F5 31±1.4142 84.44±2.96
F6 23±2.2803 96.66±1.41
F7 26±2.0000 84.24±6.02
F8 17±1.4142 96.66±5.40
F9 11±1.4142 125.80±5.10
*All values are expressed as mean± SE, n=3.
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Figure 8.18:Wetting profile of mouth dissolving Loratadine tablets
(F1 - F9)
Figure 8.19:Water absorption ratio of mouth dissolving Loratadine tablets
(F1 - F9)
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8.3.8. In –Vitro Dissolution Studies
Dissolution profile of mouthdissolving Loratadine tablet
Table 8.17: In-vitro dissolution data of formulation F1
S. No.
Time
(minutes)
Amount of
drug released
(mg)
%DE
MDT
(minutes)
Cumulative %
drug Release
1 0 0.00 0.00 0.00 0 ± 0.00
2 3 7.28 36.04 1.50 72.91±0.6266
3 6 7.64 55.24 1.69 76.42 ± 0.7985
4 9 8.54 63.84 2.26 85.5 ± 0.6221
5 12 8.81 69.60 2.57 88.14 ± 0.2214
All the values are expressed as a mean ± SD., n = 3
MDT=Mean dissolution time; % DE= Percent dissolution efficiency
Figure 8.20: Cumulative % drug release profile of formulation F1
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Dissolution profile for formulation F2
Table 8.18: In-vitro dissolution data of formulation F2
S. No.
Time
(Minute)
Amount of
drug released
(mg)
%DE
MDT
(Minute)
Cumulative %
drug Release
1 0 0.00 0.00 0.00 0.00
2 3 7.63 37.96 1.50 76.34 ± 0.98
3 6 8.06 58.12 1.68 80.88 ± 0.94
4 9 8.78 66.72 2.11 87.34 ± 0.854
5 12 9.23 72.32 2.51 91.79 ± 1.097
All the values are expressed as a mean ± SD., n = 3
Figure 8.21: Cumulative % drug release profile of formulation F2
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Dissolution Profile for Formulation F3
Table 8.19: In-vitro dissolution data of Formulation F3
S. No.
Time
(Minute)
Amount of
drug released
(mg)
%DE
MDT
(Minute)
Cumulative % drug
Release
1 0 0.00 0.00 0.00 0.00
2 3 23.48 39.00 1.33 78.31 ± 1.0102
3 6 25.14 41.21 1.42 83.81 ± 0.9072
4 9 8.99 44.06 1.53 90.01 ± 1.7596
5 12 9.35 45.61 1.58 93.54 ± 0.9073
All the values are expressed as a mean ± SD., n = 3
Figure 8.22: Cumulative % drug release profile of formulation F3
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Dissolution Profile for formulation F4
Table 8.20: In-vitro dissolution data of formulation F4
S. No.
Time
(minute)
Amount of
drug released
(mg)
%DE
MDT
(Minute)
Cumulative %
drug Release
1 0 0.00 0.00 0.00 0.000 ± 0.00
2 3 7.01 35.07 1.50 70.20± 1.9053
3 6 8.22 53.80 1.69 74.05± 0.5212
4 9 8.9 61.71 2.07 80.16 ± 1.0627
5 12 9.48 66.95 2.57 85.43 ± 0.5692
All the values are expressed as a mean ± SD., n = 3
Figure 8.23: Cumulative % drug release profile of formulation F4
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Dissolution Profile for Formulation F5
Table 8.21: In-vitro dissolution data of Formulation F5
S. No.
Time
(Minute)
Amount of
drug released
(mg)
%DE
MDT
(Minute)
Cumulative % drug
Release
1 0 0.00 0.00 0.00 0.00
2 3 7.25 36.34 1.50 72.58 ± 0.4653
3 6 7.93 56.11 1.74 79.36 ± 1.5224
4 9 8.32 64.56 2.07 83.30 ± 2.9131
5 12 8.78 69.86 2.45 87.89 ± 1.3618
All the values are expressed as a mean ± SD., n = 3
Figure 8.24: Cumulative % drug release profile of formulation F5
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Dissolution profile for formulation F6
Table 8.22: In vitro dissolution data of formulation F6
S. No.
Time
(Minute)
Amount of drug
released
(mg)
%DE
MDT
(Minute)
Cumulative % drug
Release
1 0 0.00 0.00 0.00 0.00
2 3 7.60 38.15 1.50 76.13 ± 0.9595
3 6 8.09 58.30 1.66 80.97 ± 1.3054
4 9 8.74 66.83 2.10 87.52 ± 0.5105
5 12 9.09 72.38 2.44 90.96 ± 0.6814
All the values are expressed as a mean ± SD., n = 3
Figure 8.25: Cumulative % drug release profile of formulation F6
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Dissolution profile for Formulation F7
Table 8.23: In-vitro dissolution data of Formulation F7
S. No.
Time
(Minute)
Amount of
drug
released
(mg)
%DE
MDT
(Minute)
Cumulative %
drug Release
1 0 0.00 0.00 0.00 0.00 ± 0.00
2 3 7.60 38.18 1.50 76.07 ± 0.3220
3 6 8.11 58.46 1.68 81.24 ± 0.9209
4 9 8.70 67.04 2.09 87.09 ± 0.1330
5 12 9.19 72.63 2.47 91.92 ± 0.6291
All the values are expressed as a mean ± SD., n = 3
Figure 8.26: Cumulative % Drug release profile of formulation F7
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Dissolution profile for Formulation F8
Table 8.24: In-vitro dissolution data of Formulation F8
S. No.
Time
(Minute)
Amount of
drug
released
(mg)
%DE
MDT
(Minute)
Cumulative %
drug Release
1 0 0.00 0.00 0.00 0.00 ± 0.00
2 3 8.10 40.61 1.50 81.11 ± 1.0369
3 6 8.51 62.65 1.66 85.20 ± 0.8182
4 9 9.01 70.71 1.95 90.13 ± 2.2305
5 12 9.61 76.40 2.51 96.17 ± 2.112
All the values are expressed as a mean ± SD., n = 3
Figure 8.27: Cumulative % Drug release profile of formulation F8
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Dissolution Profile for formulation F9
Table 8.25: In-vitro dissolution data of formulation F9
S. No.
Time
(Minute)
Amount of
drug
released
(mg)
%DE
MDT
(Minute)
Cumulative %
drug Release
1 0 0.00 0.00 0.00 0.00 ± 0.00
2 3 9.49 42.92 1.50 85.42 ± 1.6733
3 6 9.17 65.79 1.68 91.78 ± 0.9055
4 9 9.69 75.33 2.04 96.40 ± 1.5832
5 12 9.90 81.12 2.23 99.10 ± 0.9422
All the values are expressed as a mean ± SD., n = 3
Figure 8.28: Cumulative % drug release profile of formulation F9
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Figure 8.29: Cumulative % drug release profile of formulation F1 – F3
Figure 8.30: Cumulative % drug release profile of formulation F4 – F6
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Figure 8.31: Cumulative % drug release profile of formulation F7 – F9
Dissolution Profile of Mouth Dissolving Loratadine Tablets (F1 - F9)
Figure 8.32: Cumulative % drug release profile of formulation F1 – F9
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8.4. STABILITY STUDIES
8.4.1 Ageing studies for optimized formulation F9 of mouth dissolving Loratadine tablet at
accelerated condition of 40oC ± 2oC/75% RH ± 5% (Initial)
Table 8.26: Stability results (Initial)
S. No. Evaluation Parameter
Observation
Formulation – F9
1 Physical Appearance White,round, break-through, flat tablet.
2 Hardness (kg/cm2) 3.0 ± 0.1
3 Disintegrate test (seconds) 12 ± 1.8973
4 Dissolution test (%) 99.10 ± 0.9422
5 Drug content (% w/w) 98.75 ± 0.01
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8.4.2. Ageing studies for optimized formulation F9 of mouth dissolving Loratadinetablet at
accelerated condition of 40oC ± 2oC/75% RH ± 5% (1stmonth)
Table 8.27: Stability results (1stmonth)
S. No.
Evaluation Parameter Observation
Formulation – F9
1 Physical Appearance ****
2 Hardness (kg/cm2) 2.93 ± 0.577
3 Disintegrate test (seconds) 11.80 ± 1.632
4 Dissolution test (%) 99.02 ± 0.0115
5 Drug content (% w/w) 98.73 ± 0.17
**** = No Change
8.4.3. Ageing studies for optimized formulation F8 of mouth dissolving Loratadine tablet
at accelerated condition of 40oC ± 2oC/75% RH ± 5%(2ndmonth).
Table 8.28: Stability results (2ndmonth)
S. No.
Evaluation Parameter Observation
Formulation – F9
1 Physical Appearance ****
2 Hardness (kg/cm2) 2.93 ± 0.681
3 Disintegrate test (seconds) 11.65 ± 0.632
4 Dissolution test (%) 98.52 ± 0.0416
5 Drug content (% w/w) 98.70 ± 0.20
**** = No Change
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8.4.4. Ageing studies for optimized formulation F8 of mouth dissolving Loratadinetablet at
accelerated condition of 40oC ± 2oC/75% RH ± 5% (3rdmonth)
Table 8.29: Stability results (3rd month)
S. No.
Evaluation Parameter Observation
Formulation – F9
1 Physical Appearance ****
2 Hardness (kg/cm2) 2.90 ± 0.516
3 Disintegrate test (seconds) 11.55 ± 1.471
4 Dissolution test (%) 98.70 ± 0.264
5 Drug content (% w/w) 98.64 ± 0.18
**** = No Change
8.4.5. Comparative Stability In–Vitro Release Study of optimized F9 formulation
Table 8.30: Comparative In-vitro dissolution data of formulation F9
Time in
minute
Cumulative % Release of Loratadine
(Mean ± S.D., n = 3)
Initial First month Second month Third month
05 85.42 ± 1.673 85.10 ± 0.1 84.22 ± 0.230 83.99 ± 0.09
10 91.78 ± 0.905 90.68 ± 0.13 88.78 ± 0.1501 86.56 ± 0.103
15 96.40 ± 1.583 96.10 ± 0.1 94.56 ± 0.103 92.78 ± 0.04
30 99.10 ± 0.942 99.02 ± 0.011 98.52 ± 0.041 98.70 ± 0.264
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Figure 8.33: Comparative % Drug release of all three months with initial of optimized
formulation F9.
8.4.6. Comparative Ageing studies for optimized formulation F9 with initial results
Table 8.31: Stability results (Initial to 3rdMonth)
S. No. Evaluation
Parameter
Formulation- F9  observations
Initial First
month
Second
month
Third
month
1
Physical
Appearance
White, round,
Break -
through, flat
tablet.
No change No change No change
2 Hardness (kg/cm2) 3.0±0.1 2.93±0.12 2.93±0.23 2.90 ± 0.1
3 Disintegrate test
(seconds) 12±1.897 11.80±1.673 11.65±1.522 11.55±1.79
4 Dissolution test
(%) 99.1± 0.9422 99.02±0.01 98.52±0.041 98.70±0.264
5 Drug content
(% w/w) 98.75±0.01 98.73±1.123 98.70±0.114 98.64±0.136
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Figure 8.34: Comparison of Hardness for formulation  F9 with initial and different
stability period
Figure 8.35: Comparison of Disintegrate time for formulation F9 with initial and
different stability period
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Figure 8.36: Comparison of Drug release for formulation F9 with initial and
different stability period
Figure 8.37: Comparison of Drug content for formulation F8 with initial
and different stability period
Stability studies of formulation F9 were carried out by placing the samples at
temperature 40oC and different relative humidity conditions 75% RH. From the above
observations it was found that there were no significant changes in disintegrate time,
release characteristics and physicochemical properties of the tablets used in the release
study. Based on the results it can be concluded that the formulated mouth dissolving
tablets were stable at accelerated stability conditions (40oC ± 2oC and 75% ± 5% RH) over a
period of 3 months. Even though its stability is assured for three months, further studies as
per the ICH guidelines are to be needed to establish its shelf-life.
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and
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9. SUMMARY AND CONCLUSION
The present investigation was undertaken to fabricate and evaluate instant release
mouth dissolving tablet of Loratadine with the main objective of quick onset of action
followed by pleasant mouth feel and improved patient compliance.
Loratadine is act as an anti histaminic and used as potential drug to get the quick
relief in suddenly arising allergic reactions like urticaria, angeoedema, in treatment of
perennial and seasonal allergic rhinitis, considering this parameter there is a need formulate
the Loratadine as fast disintegrating mouth dissolving tablet. Present Mouth dissolving tablet
by passes the hepatic metabolism unlikely of the other conventional oral dosage forms which
are relatively less bioavailable. This MDT gives absorption of drug from oral cavity, pharynx
and oesophagus; results in quick onset of action, improved bioavailability and patient
compliance.
The present study is an attempt to select best possible combination of
superdisintegrants to formulate MDDDS of Loratadine which disintegrates within seconds in
mouth, thereby reducing the time of onset of action, with maximum bioavailability of
Loratadine.
Sodium starch glycollate, Crospovidone and Croscarmellose sodium were selected as
super disintegrants. Microcrystalline cellulose is selected as diluents and it also act as a
disintegrant in the lesser extent. Likewise the Mannitol used as diluents and it have the
property to produce cooling sensation in the mouth. Aerosil added as a glident in all
formulations in same concentrations. Magnesium sterate as a lubricant. Aspartame was
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incorporated as sweetening and taste inhibiting agent. Whereas, strawberry used as flavoring
agent, for to get the cool and pleasant mouth feel.
Drug-excipients interaction study was carried out using FT-IR i.e. by KBr pellet
method (1:1). The FT-IR spectra revealed that there was no compatibility related problems
between the drug and excipients used in the formulation.
Direct Compression method was used to formulate the tablets, because of its cost
effectiveness, reduced number of manufacturing steps.
Pre-compression parameters; bulk density, tapped density,Compressibility index and
Hausner’s ratio for all formulations were found to be in good agreement of the prescribed
limits. Showed good powder flow properties.
Post-compression parameters; hardness, friability, weight variation, drug content was
evaluated and found to be acceptable with the prescribed limits.
Wetting time and swelling capacity of disintegrants are the important parameters for
comparing efficiency of disintegrate process. The use ofhighest concentration of
Crospovidone in F9 formulation showed highest hydration and swelling capacity of 11
seconds  and 125.80 % respectively. Crospovidone has 5 to 10 folds more swelling capacity
in just 10 seconds. Crospovidone showed faster disintegrate followed by Croscarmellose
sodium and Sodium starch glycollate formulations.
Disintegrate time for all formulations was found in between 12 ± 1.67 to 30 ± 1.89
seconds. Disintegrate time was found to be very less for F9 formulation which contains
highest concentration of Crospovidone.
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Percent cumulative drug release for all nine formulations was found in the range of
88.94 ± 0.2214 to 99.10 ± 0.9422 %. Drug release was increased with the increased
concentration of  with crosspovidone. F9 formulation showed highest drug release i.e.
99.10% w/w in almost first 12 minutes.
In the present study, attempt was made to formulate instant palatable mouth
dissolving tablets of Loratadine. From the studies carried out and above obtained results
following conclusions are drawn;
Mouth dissolving tablet of Loratadine can be successfully prepared using selected
different superdisintegrants, diluents and taste inhibiting agents by sensory approach using
Direct Compression method.
Formulation F9 revealed promising results which was formulated by Crosspovidone
in 5:4 ratio. This formulation exhibited highest water absorption and hydration capacity,
showed least disintegrate time and highest percent drug release which provides quick onset
of action and immediate relief in suddenly arising allergic reactions. Moreover, they showed
pleasant mouth feel. This formulation satisfied all the tablet evaluation parameters for Mouth
Dissolving Drug Delivery System. Hence, it was concluded that the F9 Formulation is
optimized formulationamongst F1 to F9.
Optimized Formulation F9 was tested for Accelerated stability as per ICH guidelines
was found to be a stable at 40oC ± 2oC temperature and 75% ± 5% relative humidity for three
months.
Undoubtedly Loratadine MDT will surely give the rapid onset of action, quick relief,
low side effects, pleasant mouth feel, good stability, improved patient compliance, and its
popularity in the near future.
Future
Prospectus
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10. SCOPE FOR FURTHER STUDY
SCOPE FOR FURTHER STUDY
In the present work the mouth dissolving tablets Loratadine  were prepared by using
different superdisintegrants as Croscarmellose sodium, Sodium starch glycollate and
Crospovidone by direct compression method. In this work only physiochemical
characterization, formulation and in-vitro evaluation of Mouth dissolving tablets Loratadine
was performed. Along with in-vitro studies in-vivo studies of drug is most important. In
future in-vivo studies are required to set the in-vitro in-vivo correlation which is necessary for
development of successful formulation and also long term stability studies are necessary.
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